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RYAN-1MRSFMAN, MILLYy Ph.D. Mealtime Food Intake and Behavior of 
Normal Weight Adult Males: Effects of Phenylalanine and 
Aspartame. (1987) Directed by Dr. Lucille M. Wakefield and Dr. 
G. Harvey Anderson. 107 pp. 
Ttoo experiments were conducted to investigate the 
neurobehavioral effects of phenylalanine (PHE; 0.84, 2.52y 5.04, 
and 10.08 g) and aspartame (APM; 5.04 and 10.08 g) on energy and 
macronutrient selection and on subjective feelings of hunger, mood 
and arousal in normal weight adult males. Neither PHE nor APM 
altered mean energy intakes or macronutrient selection during 
lunch which began 60 or 105 min after the amino acids were 
consumed. During this time, increased (p < .05) visual analog 
scale scores for emptiness, rumbling, weakness, degree of hunger 
and urge to eat were found in both experiments, but no treatment 
effects or interactions were seen for any variable in either 
experiment. Plasma amino acid levels were measured after capsule 
administration at 45 min in experiment 1 and at 90 min in 
experiment 2 and were compared to baseline samples. Plasma PHE 
levels and ratios to other large neutral amino acids (NAA) rose 
significantly (p < .05) after all treatments except 0.84 g PHE; 
plasma tyrosine (TYR) levels increased (p < .05) only when greater 
than 2.52 g PHE was given. TYR/NAA ratios were higher (p < .05) 
after 2.52 and 5.04 g PHE, and 10.08 g APM. No relationships were 
found between food intake and plasma amino acid levels. 
A third experiment was performed to further test the 
neurobehavioral effects of PHE, as AFM, on subjective feelings of 
hunger, mood and arousal and on plasma amino acid levels. APM or 
placebo (10.08 g) capsules were administered concurrently with a 
high carbohydrate (118 g) breakfast at 8 a.m. Visual analog 
scales (administered at 8 a.m., 10 a.m., 12 noon and 2 p.m.) 
showed no treatment effects or interactions for any variable in 
this experiment, but time affected scores for errptiness, hunger, 
and urge to eat. When absolute and relative plasma amino acid 
levels at 90 min following the high carbohydrate breakfast were 
compared to baseline values, plasma FHE, TYR, and tryptophan (TOP) 
levels decreased (p < .05). The PHE/NAA ratio increased (p < 
.05), but TYR/NAA and TRP/NAA ratios were unchanged. When APM was 
given with the high carbohydrate breakfast, plasma FHE and its 
ratio to the other large NAA increased (p < .05), but the increase 
in TYR and the TYR/NAA ratio was not significant. Plasma TOP 
decreased (p < .05), but the TOP/NAA ratio was not significantly 
decreased. The author concludes that PHE, when given as the free 
amino acid or as ARV1 in doses up to 10 g, does not affect feeding 
behavior in normal weight adult males, even when administered 
concurrently with carbohydrate. 
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CHAPTER I 
INTRODUCTION 
Although the brain comprises only 2% of adult body weight, this 
organ receives 15% of cardiac output and accounts for 20-30% of the 
resting metabolic rate (Solokoff, Fitzgerald, & Kauffman, 1977). 
Logically then, because the central nervous system (CMS) demands a 
steady influx of nutrients, it could be involved in regulating 
energy and macronutrient (protein, carbohydrate and fat) intakes. 
Much research has been focused on the regulation of energy intake, 
but only recently have the putative roles of the macronutrients in 
regulating feeding behavior been explored. Brain neurotransmitters, 
such as the catecholamines norepinephrine and dopamine, may play a 
key role in appetite regulation through their influence on energy 
intake and macronutrient selection in the diet. Amino acids serve 
as precursors in the synthesis of brain neurotransmitters, but the 
effect of bolus doses of single amino acids on food intake has not 
been investigated thoroughly. The importance of understanding 
mechanisms which control appetite is apparent when studying eating 
disorders such as obesity. Differences in the regulation of feeding 
behavior may exist between normal and obese individuals. Whether 
these possible differences exist prior to onset of weight gain or as 
a result of obesity is unknown. However, obese people often attempt 
to reduce caloric intake by substituting artificial sweeteners for 
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sucrose; therefore, understanding the effect of artificial 
sweeteners on food intake regulation is an important research goal. 
Aspartame (AFM), a relatively new non-nutritive sweetener which is 
widely used in foods in many countries, contains approximately 50% 
by weight of phenylalanine (PHE), the amino acid precursor to the 
catecholamines. 
Purpose and Objectives 
The purpose of this project was to test the effect of premeal 
consumption of PHE, as the free amino acid or as AFM, on short-term 
energy intake (kcal), macronutrient selection (percent protein, 
carbohydrate, fat), and subjective feelings of hunger, mood and 
arousal during lunch time in normal weight adult males. 
The specific objectives were the following: 
1) to examine the effect of large intakes (up to 10 g) of PHE on 
energy intake and macronutrient selection in a meal 2) to examine 
the effect of large intakes (up to 10 g) of APM on energy intake and 
macronutrient selection in a meal 3) to measure the effects of 
premeal consumption of PHE and/or AFM on subjective feelings of 
hunger, mood and arousal as assessed by Visual Analogue Scales (VAS; 
Maxwell, 1978) 4) to determine the effect of administration of PHE 
or APM on plasma levels of the large neutral amino acids (NAA) PHE, 
tyrosine (TYR), tryptophan (TRP), leucine, isoleucine and valine, 
and on the relative concentrations of PHE, TYR and TRP to the other 
NAAs (e.g., PHE/NAA) 5) to determine whether the concurrent 
consunption of a high carbohydrate breakfast (118 g) with APM (10 g) 
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will enhance the effect of PHE on subjective feelings of hunger, 
mood and arousal and 6) to investigate whether the concurrent 
consumption of a high carbohydrate (118 g) breakfast with APM (10 g) 
will alter the absolute and relative plasma concentrations of PHE, 
TYR and TRP. 
Hypotheses 
The following null hypotheses were tested: 
1) premeal consumption of PHE and APM will have no effect on energy 
intake and macronutrient selection in a meal consumed by normal 
weight adult males 2) premeal consumption of PHE and APM will have 
no effect on plasma NAAs in normal weight adult males 3) premeal 
consumption of PHE and APM will have no effect on subjective 
feelings of hunger, mood and arousal in normal weight adult males 4) 
concurrent consumption of a high carbohydrate breakfast with APM 
will have no effect on plasma NAA levels and 5) concurrent 
consumption of a high carbohydrate breakfast with ARVI will have no 
effect on subjective feelings of hunger, mood and arousal in normal 
weight adult males. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Overview of Appetitive Mechanisms 
Mechanisms by which the CNS may regulate feeding behavior must 
be reviewed before discussing the possible effects of PHE and APM on 
control of appetite. Of primary interest is that the hypothalamus 
was identified as the portion of the brain involved in the feeding 
mechanism. The ventromedial hypothalamus (VMH) is associated with 
satiety while the lateral hypothalamus (LH) is described as the 
feeding center (.Anderson, Li, & Glanville, 1984). However, 
subsequent to hypothalamic experiments, evidence was presented which 
indicated that catecholaminergic and serotoninergic fiber tracts 
cross the hypothalamus; the introduction of brain lesions in the 
hypothalamic area to study feeding behavior may actually damage 
these important neuronal systems (Grossman, 1972; Mogenson, 1974). 
In experimental animals, the manipulation of brain neurotransmitter 
(serotonin, norepinephrine, dopamine) systems may alter feeding 
responses. 
The classic glucostatic and aminostatic theories of appetite 
control cannot be overlooked in a discussion of feeding behavior. 
Louis-Sylvestre and Le Magnen (1980) observed a 7% decrease in blood 
glucose concentration prior to the onset of eating in the rat. This 
observation supports the glucostatic theory of appetite control, 
i.e., the brain responds directly to alterations in blood glucose 
concentration. However, the glucostatic theory of appetite control 
can be challenged by the observation that hypoglycemia (Strieker, 
Rowland, & Sailer, 1977) and hyperglycemia (Rezek, Havlicek, & 
Novin, 1975) do not always influence feeding. Because blood glucose 
concentration does not necessarily indicate the rate of glucose 
utilization by tissues, brain cellular glucose utilization may be 
more closely related to feeding behavior (Anderson et al., 1984). 
Satiation in animals corresponds with a high rate of cellular 
glucose utilization (Glick & Mayer, 1968) while a low rate of 
cellular glucose utilization by tissues is associated with eating 
(Miller, Paneri, Cocchi, Frohman, & Mantegazza, 1973). 
Hie aminostatic theory of appetite control originated from the 
observation that an inverse relationship existed between serum amino 
acid concentration and appetite in man (Mellinkoff, Franklin, Boyle, 
& Geipell, 1956). From this research, Mellinkoff et al. (1956) 
concluded that, to control appetite, the brain monitored shifts in 
the plasma amino acid pattern. The protein specific appetite of 
rats was first described by Musten, Peace, and Anderson (1974). 
Young rats were given two diets which differed in protein content; 
both diets contained identical nutrient to energy ratios and were 
nutritionally complete. Yet, the rats were able to regulate their 
protein intake from the two diets at a constant proportion of total 
dietary energy. Cold exposure (Leshner, Collier, & Squibb, 1971) or 
increased activity (Collier, Leshner, & Squibb, 1969) caused rats to 
adjust food intake to meet the increased energy requirement, but the 
proportion of protein consumed remained unchanged. Overall, the 
rats chose a diet which resulted in normal growth. 
Diet and Brain Neurochemistry 
Currently, research is being conducted to determine if 
neurotransmitters play a role in appetite regulation. The feeding 
of dietary protein elicits a shift in both plasma and brain amino 
acid patterns in rats; this shift may influence subsequent feeding 
behavior through neurotransmitter synthesis (Tews, Good, & Harper, 
1978). Until recently, diet was thought to influence brain 
biochemistry and function only when biochemical and clinical 
evidence of nutrient deficiency was present. The provision of amino 
acids, monoamines and peptides for brain neurotransmitter synthesis 
was thought to be independent of diet for two reasons. Scientists 
believed the brain could produce sufficient quantities of substrates 
by utilizing its own resources. In addition, they believed that 
neurotransmitter synthesis was regulated by metabolic feedback where 
fluctuations in synthesis are linked to utilization, not precursor 
availability (Anderson & Johnston, 1983). However, feeding behavior 
may be directly influenced by the elevation in brain free amino acid 
pools, or may be indirectly influenced by a block in the brain's 
uptake of the NAAs (Tews et al., 1978). 
Dietary components may affect neurotransmitter synthesis by 
enhancing the transmission of neural impulses across the synapse; 
therefore, dietary alterations may result in increased 
neurotransmitter synthesis. Certain biochemical processes must 
follow in sequence if the consumption of a meal rich in a particular 
nutrient will increase the brain's synthesis of the neurotransmitter 
for which the nutrient is the precursor. No feedback mechanism can 
exist which maintains a relatively constant plasma level of the 
nutrient, and there must be no impenetrable blood-brain-barrier for 
the precursor nutrient. Both the transport mechanism that mediates 
the passage of the nutrient from blood to brain and the neuronal 
enzyme that catalyzes the conversion of the precursor nutrient into 
the neurotransmitter must be of the low affinity type, i.e., they 
must become more completely saturated when the nutrient level rises. 
Finally, the neuronal enzyme must not be susceptible to feedback 
inhibition when the intracellular level of the neurotransmitter 
rises. All of these conditions have been met for the synthesis of 
serotonin, the catecholamines dopamine and norepinephrine, and 
acetylcholine (Wurtman, 1982). 
Anderson and Johnston (1983) noted that the availability of 
dietary precursors influences the synthesis of at least five 
neurotransmitters: serotonin (TRP), catecholamines (TYR), 
acetylcholine (lecithin and choline), histamine (histidine), and 
glycine (threonine). The relationship between dietary intake of TRP 
and serotonin synthesis has been established in many studies (Ashley 
& Anderson, 1975; Fernstrom, Larin, & Wurtman, 1973; Fernstrom & 
Wurtman, 1971a; Fernstrom & Wurtman, 1971b; Fernstrom & Wurtman, 
1972; Li & Anderson, 1984; Wurtman & Fernstrom, 1975). Consumption 
of a meal high in carbohydrate will increase plasma TRP levels 
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relative to other large NAAs because of the effect of insulin on 
plasma amino acids. Insulin secretion following ingestion of 
carbohydrate will enhance the uptake of large NAAs by peripheral 
tissues; but, TRP is normally bound to albumin, which prevents its 
uptake by peripheral tissues. At the level of the 
blood-brain-barrier, TOP is released from albumin because TOP has a 
greater affinity for the brain's large NAA transport system carrier. 
A reduction in plasma concentrations of the ccmpetitive amino acids 
allows more TOP to cross the blood-brain-barrier. Hence, brain TOP 
levels rise and brain serotonin synthesis is enhanced. In short, 
carbohydrate consumption increases brain serotonin while protein 
consumption decreases brain serotonin (.Anderson et al., 1984); 
consequently, rats regulate their macronutrient (carbohydrate and 
protein) intakes if appropriate dietary choices (Li & Anderson, 
1983) are available on both a day-to-day (Musten et al., 1974) and a 
meal-to-meal basis. If the previous meal constimed was high in 
carbohydrate, then the rat will choose a meal higher in protein for 
its next meal (Li & Anderson, 1982). 
Unfortunately, the relationship between dietary TYR and brain 
catecholamine synthesis is not yet clear. Elevations in plasma TYR 
may influence catecholamine synthesis; in turn, catecholamines may 
regulate energy balance (Anderson, 1979) and food choice (Wurtman & 
Wurtman, 1979). In animals, brain catecholamine synthesis seems to 
respond to food consumption and composition (Landsberg & Young, 
1978) as well as to the availability of the precursor, TYR (Gibson & 
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Wurtman, 1978; Sved & Fernstrom, 1981). Shimazu and Takahashi 
(1980) stated that norepinephrine and dopamine are both involved in 
energy expenditure; furthermore, Wurtman, Hefti, and Melamed (1981) 
reported that normal animals subjected to cold stress exhibited 
enhanced brain synthesis and release of norepinephrine upon 
administration of TYR. Leibowitz (1976) studied the roles of 
norepinephrine and dopamine in mechanisms of appetite regulation. 
Leibowitz (1976) observed that central injections of norepinephrine 
in rats caused an increase in meal size and rate of eating; the rats 
also showed a greater preference for carbohydrate. Similar 
injections of dopamine increased rate of eating and decreased 
preference for protein. Central injections of norepinephrine and 
dopamine may, however, elicit different appetite effects than those 
observed with dietary manipulation because of the various brain 
regions and receptor sites affected (Anderson et al., 1984; 
Leibowitz, 1986). 
Dopamine and norepinephrine are formed from TYR. by the 
enzymatic action of TYR hydroxylase (Fernstrom & Wurtman, 1974). 
TYR is abundant in dietary proteins and, in rats, approximately half 
of the PHE in protein is converted to TYR during each passage 
through the hepatic circulation; however, PHE is an essential amino 
acid and its conversion to TYR is probably not sufficient to meet 
the body's requirement for TYR (Wurtman et al., 1981). A recent 
study (Clarke & Bier, 1982) indicates that the rate of conversion of 
ME to TYR in man may be somewhat lower than the rate obtained from 
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PHE loading studies. Yet, the enzyme HIE hydroxylase, which 
converts PHE to TYR, is also present in catecholamine synthesizing 
neurons (Bagchi & Zarycki, 1973). 
Some evidence exists which supports the concept that the 
rate-limiting factor in brain catecholamine synthesis is TYR 
hydroxylase activity, but data presented by Wurtman, Larin, 
Mostafapour, and Fernstrom (1974) suggest that brain TYR 
concentration may be an additional factor. The administration of 50 
mg/kg of TYR caused, after 45 min, an 81% increase in brain TYR and 
a 13% increase in the accumulation of dopa (p < .05) in rats. A 50 
mg/kg dose of PHE did not significantly enhance dopa synthesis, 
although brain TYR levels were elevated (Wurtman et al., 1974). 
Agharanya, Alonso, and Wurtman (1981) reported that accelerated 
catecholamine synthesis can be achieved in the human sympathoadrenal 
system by TYR administration, most likely by enhancing saturation of 
TYR hydroxylase. However, Fernstrom (1984) noted that brain TYR 
levels must increase twofold before TYR hydroxylase activity is 
enhanced. A short-term increase in the physiological activity of 
catecholaminergic neurons, such as occurs during stress, can 
accelerate the conversion of TYR to a catecholamine, perhaps by 
decreasing the end-product inhibition of TYR hydroxylase by 
norepinephrine. Also, TYR hydroxylase activity is increased with 
long-term enhancement of the physiological activity of 
catecholaminergic neurons (Wurtman & Fernstrom, 1975). Wurtman 
(1983a) stated that the biochemical mechanism which links the firing 
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frequency of a neuron to its responsiveness to TYR apparently 
involves the activation of TYR hydroxylase by phosphorylation. 
Phosphorylation of TYR hydroxylase increases the enzyme's affinity 
for TYR and diminishes the enzyme's sensitivity to feedback 
inhibition by catecholamines. Therefore, the brain selects which 
catecholaminergic neurons will be allowed to respond to increased 
precursor levels by modulating the firing frequencies of the 
neurons; this event is not observed in serotoninergic neurons 
(Wurtman, 1983a). 
Because a single mechanism mediates the uptake of all the large 
NAAs by the brain, the passage of TYR through the 
blood-brain-barrier can be accelerated either by raising plasma TYR 
levels or by lowering plasma levels of other NAAs. Although insulin 
facilitates the uptake of TYR into skeletal muscle, plasma TYR 
levels are not lowered to as great an extent as are the 
branched-chain NAAs (leucine, isoleucine, and valine) which are 
metabolized primarily in muscle. Therefore, a protein-free meal 
will cause no change or only a small increase in the plasma ratio of 
TYR/NAA, but a meal containing protein will increase the plasma 
TYR/NAA ratio and possibly accelerate the synthesis of 
catecholamines (Wurtman et al., 1981). 
The specific effect of bolus doses of PHF, on food intake and 
brain neurotransmitter synthesis has received even less attention 
than the effect of TYR on catecholamines and food intake. PHE 
administration by intragastric infusion has been shown to suppress 
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food intake in rats (Anika, 1982)y dogs (Meyer & Grossman, 1972), 
and monkeys (Gibbs, Falasco, & McHugh, 1976). This appetite 
suppressing effect of PHF. has been ccmnonly attributed to the fact 
that PHE is a potent gut cholecystokinin (OCX) secretogogue (Walsh, 
1981). However, the possible influence of PHE on brain 
catecholamine synthesis and food intake cannot be ignored. 
Catecholamines and Obesity 
Although obesity has been thoroughly investigated, the causes 
are still unidentified. Wooley (1971) studied the long-term effects 
of caloric density of food and self-reported hunger in obese and 
non-obese individuals. No significant differences were observed in 
energy intakes between normal and obese individuals, but obese 
subjects' hunger ratings increased throughout the study while normal 
subjects' hunger ratings remained consistently low. Wooley (1971) 
concluded that obese subjects' hunger was appetitive (ratings 
increased in response to the presence of nonexperimental food), but 
normal subjects' hunger was physiological. Nevertheless, studies 
have indicated that obesity may have a physiological nature, e.g., 
obesity may be associated with abnormal catecholamine metabolism. 
Catecholamine metabolism has been shown to be altered in obese 
rodents (Goscina, McArthur, Stancer, & Godse, 1978; Cruce, Thoa, ft 
Jacobowitz, 1978; Orosco, Jacquot, & Cohen, 1981). In a study by 
Johnston, Warsh, and Anderson (1983), baseline urinary excretion of 
3-me thoxy-4-hydroxy phenylethyleneglycol (MHPG), a norepinephrine 
metabolite, was associated with body fat content, while excretion of 
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the norepinephrine metabolite vanilmandelic acid CVIV&) was related 
to lean body mass and total energy intake in 12 normal subjects. 
These relationships were not observed in nine obese females. Normal 
subjects responded to TYR with elevations in plasma TYR/NAA, MHPG, 
VMA and hamovanillic acid (HVA, a dopamine metabolite), but not 
dihydroxy phenylethyleneglycol (DHPG). In the obese, only VMA and 
HVA excretion increased with TYR supplementation, and these women 
also exhibited altered circadian rhythms. Johnston et al. (1983) 
concluded that, if, as believed, the majority of MHPG originates in 
the brain, the relationship between MHPG and body fat may indicate 
that central norepinephrine metabolism is linked to energy storage 
in normal weight subjects, but not in obese subjects. An 
investigation into the effects of PHE on food intake and brain 
catecholamine synthesis in experimental animals and to the extent 
possible in normal weight humans must be conducted before 
comparisons of PHE's effects can be made between obese and normal 
weight subjects. 
Artificial Sweeteners and Weight Control 
In view of the proposed mechanisms by which the ("NS regulates 
appetite, is it possible to achieve weight loss by replacing sucrose 
in the diet with low calorie artificial sweeteners? The effects of 
artificial sweeteners on food consumption were investigated as early 
as 1933. Rats on an ad lib diet preferred glucose and saccharin 
sohitions to water. When the rats drank sugar solutions, they kept 
caloric intake constant by reducing food intake (Hausmann, 1933). 
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Sheffield and Roby (1950) reported that hungry animals, but not 
satiated animals, responded appropriately to a stimulus when 
saccharin was available as a reward. Friedhoff, Simon, and 
Friedhoff (1971) reported that mice forced to ingest water 
containing sucrose ate less solid food than those drinking either 
plain water or artificially sweetened water. The value of low 
calorie beverages for weight control or weight reduction was 
questioned by Friedhoff et al. (1971) because an individual could 
replace calories missing in the beverages with other foods, and 
furthermore, ingestion of sugar-containing beverages may not 
increase body weight because spontaneous reduction of solid food 
intake may occur. 
McCann, Trulson, and Stulb (1956) studied a group of 147 obese 
individuals. Because 43% of the subjects used non-caloric 
sweeteners and/or artificially sweetened products, the group was 
divided into users and non-users. Individuals in both groups lost 
weight; there was no significant difference in weight loss between 
the two groups. The length of time non-caloric sweeteners were used 
did not alter the patterns of weight loss. Also, no relationship 
existed between the degree of obesity and the use of non-caloric 
sweeteners. Farkas and Forbes (1965) reported that adherence to a 
carbohydrate-restricted diet was independent of the use of 
low-calorie sweeteners in 100 diabetics tested. Parham and Parham 
(1980) compared 57 women who used saccharin seven or more times 
weekly (mean = 11.3 times/week) with 45 women who used saccharin 
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less frequently (mean = 1.0 times/week). Among saccharin users, 
41.5% stated that they needed to lose weight while only 17.9% of the 
non-users thought they needed to lose weight. Although the 
saccharin users consumed significantly (p < .05) fewer servings per 
week of nutritive sweeteners and foods containing them, the 
saccharin users still reported consuming 23 servings per week. In 
addition to substituting saccharin for sugar, the users consumed 
significantly (p < .05) less bread, bakery products and soft drinks 
than the non-users. The saccharin users also maintained lower (p < 
.05) intakes of energy, carbohydrates, sugars, protein and iron 
which indicated that the decreased caloric intake may have been due 
to more than just the replacement of sugar with saccharin. Yet, 
Parham and Parham (1980) concluded that saccharin is mildly 
beneficial to healthy individuals who are watching their weight or 
limiting their sugar consumption. Porikos and Van Itallie (1984) 
suggested that the use of a non-caloric sweetener by subjects in the 
Parham and Parham (1980) study facilitated adherence to a diet by 
satisfying some need for sweets. 
Aspartame as an Artificial Sweetener 
ARM, more corrmonly known by its commercial name Nutrasweet, is 
a dipeptide which yields PHE, aspartic acid and methanol upon 
hydrolysis; APM has a sweetening potential 180-200 times greater 
than sucrose (Stegink, Filer, & Baker, 1977). APM was discovered 
accidentally in the G. D. Searle & Co. research laboratories in the 
early 1960's. Research scientists were conducting experiments with 
the inhibition of the gastrointestinal hormone gastrin as a possible 
treatment for ulcers, and APM was an intermediate in the synthesis 
of the hormone (Mazur, 1984). The Food and Drug Administration 
(FDA) approved APM as a tabletop sweetener (Equal) and for certain 
dry food applications in 1981; approval was extended to allow AFM's 
use in soft drinks in 1983 (The Australian Sugar Industry, 1984). 
Attempts have been made to estimate the average daily 
consumption of AEVI. Roak-Foltz and Leveille (1984) estimated the 
potential APM intake as 867 mg daily. An APM intake of 34 mg/kg 
body weight represents the 99th percentile of projected daily intake 
if APM replaces 50% dietary sucrose. However, these calculations 
were carried out before approval of APM for use in carbonated 
beverages (Stegink, 1984). In Can&da, soft drinks contain 102 to 
156 mg of APM per 10 ounce can or bottle. 
The importance of APM consumption is related to the artificial 
sweetener's possible influence, through PHE, on brain neurochemistry 
and behavior, and to its potential abilitj/ to control weight through 
weight reduction and/or maintenance. 
Aspartame and Weight Control 
The effectiveness of ATM in weight reduction and/or weight 
control has only begun to be explored. An August 1984 petition by 
The Sugar Association, Inc. before the Federal Trade Commission 
(FIC) requested immediate action be taken by the FIC against the G. 
D. Searle Co. for misrepresentation in the advertisement of its 
product, APM. The association stated that advertisements suggesting 
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that Nutrasweet and Equal may be useful in weight control were 
misleading because the company failed to disclose that no long-term 
studies had been conducted to demonstrate the effectiveness of these 
sugar substitutes in either weight control or weight reduction (The 
Sugar Association, Inc., 1984). 
Knopp, Brandt, and Arky C1976) reported that weight loss was 
apparent in two groups of young persons consuming APM (2.79 g/day) 
or a lactose placebo in the first seven weeks of study, but remained 
unchanged in the final six weeks, presumably because the subjects 
lost interest in the study. Because researchers have suggested that 
obesity occurs in individuals who have an elevated set point for 
energy storage, Porikos, Booth, and Van Itallie (1977) conducted an 
experiment to determine if the obese individual had the ability to 
defend his excess weight when challenged by a covert decrease in the 
caloric density of his diet. When APM was substituted for sucrose 
(25% reduction in caloric content of the diet), no change occurred 
in the quantity (weight) of sweet foods consumed, but caloric intake 
decreased (p < .05) from baseline by 23% (3274 kcal/day vs 2512 
kcal/day). The data indicated that the decrease in energy intake 
was due to APM substitution for sucrose to reduce caloric content, 
rather than to a rejection of APM sweetened products. However, the 
increase in caloric intake (energy intake stabilized at 86% of 
baseline) seen in period III of APM substitution may have marked the 
beginning of an adaptation period in which the obese individual 
attempts to defend his energy stores (Porikos et al., 1977). Long 
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term studies of dietary manipulation are necessary to establish this 
theory. 
Porikos and Van Itallie (1984) conducted two additional studies 
to determine the effectiveness of APM in weight reduction. APM 
substitution for sucrose caused energy intake to stabilize at 85% of 
baseline after 12 days in six normal weight men. In the second 
study, eight normal weight and five obese men (18-45% overweight) 
were compared. Cfoese subjects consumed an average of 20% more 
calories per day than controls (4131 kcal/day vs 3418 kcal/day), but 
showed the same pattern of adaptation to decreased energy intake 
(3464 kcal/day vs 2880 kcal/day). Substitution of APM for sucrose 
produced a 15% decrease in total energy intake for both groups. 
Porikos and Van Itallie (1984) concluded that APM may be useful in 
weight maintenance as well as weight loss. Yet, an undesirable 
shift in food selection that may occur with APM substitution must be 
noted. Even though APM substitution for sucrose resulted in a 
reduction of calorie intake, food preference shifted so that the 
energy deficit was partially alleviated by choosing foods high in 
fat. This shift to a higher fat intake must be viewed as a possible 
undesirable consequence of artificial sweetener consumption because 
high fat diets are believed to be associated with an increased 
prevalence of cardiovascular disease (Ball, 1980). 
Aspartame and Brain Neurochemist ry 
Despite the fact that AR1 has been approved for use as a 
tabletop sweetener and as a food additive in certain foods and 
beverages, controversy still exists concerning the effect of APM on 
brain neurochemistry. Since the FDA approved the use of APM in soft 
drinks, Wurtman (1983b) has withdrawn his support of the product. 
Wurtman (1983b) suggested that individuals with hypertension, 
Parkinson's disease, insomnia, hyperkinesia, or phenylketonuria 
heterozygotes and persons taking drugs which interact with plasma 
FHE or TYR would most likely exhibit behavioral or functional 
changes following APM ingestion. 
Fernstrom, Fernstrom, and Gillis (1983) reported that although 
APM administration in rats produced substantial elevations in both 
blood and brain levels of TYR and PHE, its administration caused 
only a small change in brain HIP, and did not significantly alter 
the activity of either TYR or TOP hydroxylase, or affect the levels 
of serotonin, dopamine or norepinephrine. In addition, APM had no 
significant effect on brain levels of the branched-chain amino acids 
leucine, isoleucine and valine. The researchers suggested that the 
anticipated decrease in serotonin synthesis was not realized because 
even a 200 mg/kg dose (which produced blood levels of PHE in rats 
comparable to those achieved in humans receiving 34 mg/kg body 
weight) of APM was not sufficient to raise blood PHE and TYR levels 
to a point where TOP uptake into the brain was inhibited, or where 
high brain PHE levels inhibited TOP hydroxylase (Fernstrom et al., 
1983). In later research, Fernstrom (1984) observed that a 50 mg/kg 
body weight dosage of APM raised blood and brain TYR and PHE 
concentrations in rats, but did not reduce brain TOP levels. 
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Femstrom (1984) noted that TYR levels in the blood and brain may 
have risen because 1) PHE may have been hydroxylated to TYR in the 
liver, causing blood levels of TYR to rise 2) higher plasma TYR 
levels may have allowed TYR to more effectively ccmpete with other 
NAA for transport into the brain and 3) PHE is a substrate for TYR 
hydroxylase in the brain. Fernstrom (1984) concluded that: 
Aspartame, even when administered to animals in amounts that 
cause large increments in brain tyrosine and phenylalanine 
concentrations, produces minimal effects on the brain levels of 
other [NAA], on the rates of formation of the monoamine 
transmitters, and on the pharmacological potency of centrally 
acting [NAA] drugs. 
In experiments with various groups, the results have largely 
demonstrated that APM consumption has no adverse effects on brain 
neurochemistry. Visek (1984) and Frey (1976) reported that no 
significant differences in plasma HIE, TYR or PHE to TYR ratios were 
observed in healthy children and adolescents consuming AWI. Plasma 
TYR levels were slightly, but not significantly, higher during AHVJ 
administration in young people participating in a weight reduction 
program (Knopp et al., 1976). Stegink, Filer, Baker, and McDonnell 
(1980) reported that administration of 100 mg/kg APM caused PHE 
levels to be significantly higher (p < .02) in phenylketonuria (PKU) 
heterozygous adults than in normal adults. Metabolism of PHE was 
slower in heterozygous adults because of decreased levels of PHE 
hydroxylase in the liver, and the expected increase in plasma TYR 
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levels was delayed in PKU heterozygotes. Although metabolism of PHE 
was slower in PKU heterozygous adults, Stegink et al. (1980) 
concluded that the metabolism was adequate to clear an abuse dose 
(greater than 34 mg/kg/day) of APM. Koch, Shaw, Williamson, and 
Haber (1976) also reported that no significant medical or 
biochemical changes occurred in PKU heterozygotes receiving APM 
during a 28-week study. In children with PKU, elevated plasma PHE 
levels are associated with mental retardation; however, in PKU 
children plasma PHE levels range between 180 and 300 moles/100 ml. 
After an APM load (34 mg/kg body weight), plasma PHE levels rose 
significantly (12 +_ 3 moles/dl, p < .001), but remained within 
normal postprandial limits (Stegink et al ., 1977). 1\vo normal 
adolescents and two adolescents with PKU were tested with an APM 
load (34 mg/kg/day) and a PHE load (19 mg/kg/day). No clinically 
significant alterations occurred in the subjects' excretion of PHE 
metabolites, although plasma PHE levels rose in the PKU subjects 
(Koch, Schaeffler, & Shaw, 1976). 
However, Yokogoshi, Roberts, Caballero, and Wurtman (1984) 
suggested that alterations in brain neurochemistry may occur when 
APM is consumed with carbohydrate. In a preliminary experiment with 
humans, Yokogoshi et al. (1984) determined that plasma PHE and TYR 
ratios were elevated beyond the normal ranges in six healthy 
subjects following ingestion of APM (15 mg/kg) with a snack 
providing 200 g of carbohydrate. In rats, plasma PHE levels 
increased (p < .01) by 62% and TYR levels by 142% after AWT 
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administration (200 mg/kg). Administration of glucose (3 g/kg) plus 
APM significantly increased (p < .01) plasma PHE and TYR ratios by 
causing a reduction in plasma branched-chain amino acid levels. 
Glucose administration apparently resulted in insulin secretion, 
which enhanced the uptake of the branched chain amino acids into 
muscle tissue. A 100% increase in brain PHE and a 50% increase in 
brain TYR was observed after administration of APM plus glucose. 
When APM was administered with glucose, the expected increase in the 
plasma TOP ratio was completely blocked. In addition, APM plus 
glucose resulted in a blockage of serotonin synthesis normally seen 
following carbohydrate ingestion. The 200 mg/kg dose of APM was 
given to the rats because, according to the calculations of 
Yokogoshi et al. (1984), the changes seen paralleled those which 
would be expected if 1) a 30 kg child obtained 20 mg/kg of APM by 
drinking a quart of diet beverage containing 500 mg of APM 2) the 
child consumed an additional 100 mg of APM from other dietary 
sources and 3) the child concurrently ate carbohydrate, but not 
protein. In conclusion, Yokogoshi et al. (1984) stated that 
"aspartame administration may, by elevating brain tyrosine levels, 
amplify catecholamine release from...neurons, and thus influence the 
physiological and behavioral mechanisms that they mediate." 
Subsequently, Yokogoshi and Wurtman (1986) studied the effects 
of 200 or 300 rng/kg APM on catecholamine metabolism in various 
regions of rat brain. A strain-dependent increase in regional brain 
levels of TYR or MHPG sulfate was reported following oral 
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administration of APM. Regional increases in brain norepinephrine, 
dopamine and their major metabolites following oral administration 
of APM was also observed by Coulombe and Sharma (1986), but 
serotonin and its metabolite, 5-hydroxy indole acetic acid (5-HIAA), 
were unaffected by APM. However, neither of these studies addressed 
the issue of the functional significance (through behavioral testing 
of the rats) of these brain neurotransmitter alterations. 
Much of the speculation concerning APM's effects on human brain 
neurochemistry has been extrapolated from studies of patients with 
PKU or hyperphenylalaninemia. Severe maternal hyperphenylalaninemia 
(plasma PHE levels greater than 0.6 to 1.0 rrM), can cause mental 
retardation in the fetus, but what is unclear is whether the effects 
of hyperphenylalaninemia on brain development follow a threshold or 
a linear relationship. Che would not expect mental retardation to 
occur in a fetus whose mother's plasma PHE levels were below 0.6 mM, 
but would subtle, undetectable changes in IQ occur (Pardridge, 
1986)? 
Aspartame and Behavior 
Reports concerning APM's effect on behavior in humans are 
limited. Possible behavioral side effects noted in the literature 
include disorientation, depression (Monte, 1984), nervousness, loss 
of appetite (Stern et al., 1976) or change in appetite (Knopp et 
al., 1976; Wurtman, 1983b) and emotional disturbances (Knopp et al., 
1976). Other potential neurochemically related behavioral effects 
of large doses of APM which are associated with its PHE component 
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that have been suggested include subtle changes in seizure 
thresholds in susceptible individuals, insomnia, blockade of 
therapeutic effects of drugs, menstrual irregularities, and 
cardiovascular, functions such as blood pressure regulation 
(Pardridge, 1986) . 
No symptoms, such as loss of appetite or nervousness, could be 
attributed to the administration of either APM or placebo in 
non-insulin dependent diabetic subjects (Stern et al ., 1976). In a 
chart concerning the number of side effects reported by young obese 
subjects consuming APM, five complaints of appetite change were 
reported, for subjects ingesting APM, while eight complaints of 
appetite change were listed for subjects receiving a lactose placebo 
(Knopp et al., 1976). 
Although studies (Lieberman, Corkin, Spring, Wurtman, & 
Growdon, 1985; Leathwood & Pollet, 1982/83) have clearly 
demonstrated an effect of TRP on behavior in humans, these same 
studies have failed to show any behavioral effects of TYR. The 
potential behavioral effects of PHE and APM have been virtually 
unexplored in clinical investigations. Recently, the Centers for 
Disease Control (OX) in Atlanta published an evaluation of 
anecdotal reports of adverse reactions to APM. These complaints 
were divided into three general categories - those which affect the 
central nervous system, the gastrointestinal tract, and 
gynecological function. In this report, the authors emphasized the 
importance of developing well-defined criteria to detect and 
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evaluate, in focused clinical studies, unexpected adverse reactions 
to food additives such as APM (Bradstock et al., 1986). 
In summary, two mechanisms exist by which APM may affect food 
consumption. Because APM is much sweeter than sucrose, less APM 
than sugar can be used to sweeten foods, thereby reducing the 
caloric content of sweets. If APM stibstitution for sucrose causes a 
reduction in caloric intake, then the success of APM, which has no 
bitter aftertaste, can be measured by its effectiveness in weight 
reduction in obese individuals. In addition, PHE, which can be 
readily converted to TYR, is a major constituent of AFM. Appetite 
regulation is one behavior that is likely to be sensitive to .APM 
ingestion because amino acids, such as PHE and TYR, may influence 
appetite regulatory mechanisms through precursor control of 
neurotransmitter secretion. The discovery of ARVF may lead to 
important benefits in man, but controlled experiments are necessary 
to clarify the effects of PHE and APM on food consumption. 
In the experiments reported herein, it is proposed that the PHE 
component of APM may, by enhancing the synthesis of central 
catecholamines, cause subjects to alter energy intake and 
macronutrient selection (increased preference for carbohydrate) 
during lunch time. In addition, differences may be observed in the 
subjects' perception of hunger, mood and arousal. Plasma amino acid 
levels will reflect alterations in absolute and relative 
concentrations of PHF,, TYR and TRP. 
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CHAPTER III 
METHCO 
Design 
Initially, two independent experiments were conducted with 
healthy males between the ages of 20 to 35 years, and within 90 and 
110% of ideal body weight according to the Metropolitan Life 
Insurance Co. (1983) tables. All subjects were recruited from the 
University of Toronto campus through posted notices and 
advertisements. Hie subjects gave informed consent to participate 
in the experiments, which were approved by the University of Toronto 
Human Subjects Review Comnittee. Individuals who were identified as 
possible restrained eaters because scores were higher than 40 on an 
eating habits questionnaire (Herman & Pol ivy, 1980) or those 
individuals who practiced unusual eating habits (e.g., 
vegetarianism) or those following restrictive therapeutic diets were 
excluded. 
General demographic, health, dietary and anthropometric 
information was collected for all subjects prior to each experiment. 
Habitual food selection patterns, reflecting food preferences, were 
assessed using a food frequency instrument. Height and weight were 
recorded, and triceps, biceps, subscapular and suprailiac skinfold 
thicknesses were measured with Harpenden skinfold calipers. Lean 
body mass and percent body fat were approximated from the sum of 
four skinfolds (Durnin & Womersley, 1974). 
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In experiment 1 (n = 13), four feeding trials were conducted 
following administration of capsules containing PHE in doses of 0 g 
(5.04 g alanine (ALA) placebo), 0.84 g, 2.52 g and 5.04 g. Four to 
five subjects were tested concurrently in sessions held at one week 
intervals. Hie order of treatments was double blind and randomized 
according to a randomized complete block design. 
After an overnight fast (which began at 8 p.m.), the subjects 
were given a standardized breakfast (600 kcal) which consisted of 
cereal (35 g), milk (225 ml), whole wheat bread (60 g), butter (10 
g), jam (15 g), orange juice (169 ml) and coffee or tea if 
requested. Following breakfast, the subjects were free to leave the 
test facilities, but were instructed not to consume any foods or 
beverages, except tap water, during the morning period. To disguise 
the true purpose of the experiments, subjects were advised that they 
were participating in a study examining the effect of a nutrient on 
taste perception; accordingly, taste tests were included in the 
protocol. Subjects tasted 2 g portions of four foods (ham, cheddar 
cheese, bread, chocolate cookie) without swallowing, and the 
perceived sweetness, sourness, saltiness, bitterness and overall 
liking of each food item was rated on scales which were later 
discarded. 
Visual analog scales (VAS; Maxwell, 1978) were administered at 
11 a.m. (capsules taken at 11:15 a.m.), 12 noon (buffet style 
luncheon served at 12:15 p.m.), and 12:45 p.m. to assess 17 
subjective feelings of hunger, mood and arousal. Subjects were 
asked to record their feelings regarding stomach sensations 
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(emptiness, runtoling, ache, nausea), head sensations (headache, 
dizziness, faintness), general sensations (drowsy, weak, nervous, 
tense, drugged, depressed, alert, mentally slow), degree of hunger 
and urge to eat on 100 irm unnumbered scales. The time interval (45 
min) between administration of the first and second VAS was selected 
because of its reported sufficiency in producing a maximum rise in 
plasma FHE after an oral dose (Stegink, Filer, & Baker, 1981). 
Hwelve capsules identical in appearance were administered with 
300 to 500 ml of tap water; the appropriate dose was achieved by 
mixing placebo and PHE capsules. The buffet style luncheon 
consisted of dinner rolls, butter, cold meats, cheeses and cookies; 
water was given as a beverage. All foods were pre-weighed and 
served in excess on separate trays for each subject (Table 1). 
Subjects were left alone and unobserved during lunch, but were 
instructed not to exchange foods because their food intake would be 
compared to taste test results. Following the experimental 
sessions, all leftover foods were re-weighed and meal size (kcal) 
and macronutrient (percent protein, fat, carbohydrate) selection 
were determined (from table 1.) in all trials for each of the 13 
subjects. All food preparation and testing was carried out in the 
experimental kitchen/dining facility located in the Fitzgerald 
Building at the University of Toronto. 
In experiment 2 (n = 13), conditions were similar to experiment 
1 except that doses were different and additional time (a duration 
of 90 min) was allowed between administration of PHE and APM by 
capsule and the second VAS test. The length of time between capsule 
Table 1 
Nutrient Content of Foods Served 
Amount 
Served3 Energy Density Nutrients (g/g food) 
Food (g) (kcal/g) Protein CHO*3 Fat 
Dinner Rolls 250 2.90 0.09 0.56 0.03 
Butterc 30 7.20 0 0 0.80 
Ham 250 1.40 0.20 0.01 0.06 
Salami 250 2.16 0.16 0.01 0.17 
Cheddar Cheese 200 3.72 0.25 0.02 0.30 
Havarti Cheese 200 4.29 0.21 0.01 0.38 
Chocolate Cookies 80 4.92 0.04 0.70 0.22 
Chocolate Chip 
Cookies 
110 4.83 0.05 0.65 0.23 
Fig Newtonsc 110 3.58 0.04 0.75 0.06 
a Average amount served. ^CHO = carbohydrate. ° Composition obtained 
from food composition tables; other foods by proximate analysis. 
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administration and behavioral or biochemical testing was increased 
on the chance that insufficient time was allowed for neurobehavioral 
effects of phenylalanine to occur. Doses administered were ALA 
placebo (10.08 g), 5.04 g AFM plus 5.04 g ALA., 10.08 g .ATM and 10.08 
g PHE, and VAS tests were administered at 10 a.m. (24 capsules taken 
at 10:15 a.m.), 11:45 a.m. (buffet lunch served at noon) and 12:30 
p.m. 
Sane subjects (n=5„ experiment 1; n=7, experiment 2) 
volvinteered to provide blood samples for plasma amino acid analysis. 
Venous blood was drawn on days separate from the feeding 
experiments. After an overnight fast, the subjects were given the 
same breakfast as before. A baseline blood sample was obtained 2 
1/2 hr later, immediately before capsule administration. A second 
sample was drawn 45 min (90 min in experiment 2) after the capsules 
were ingested. 
A third experiment was designed to test further the behavioral 
effects of a large dose of AFM (10 g) ingested concurrently with a 
high carbohydrate (118 g) breakfast, and to determine the effects of 
this treatment on plasma amino acid levels. 
Six male subjects, between the ages of 20 to 35 whose weights 
were between 90 and 110% ideal body weight, were recruited from the 
Department of Nutritional Sciences at the University of Toronto. 
The experiment was approved by the University of Toronto Human 
Subjects Review Committee, and subjects gave their informed consent 
to participate on two separate occasions (ATM vs. ALA placebo). 
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Ch experimental days, baseline blood samples were drawn at 7:30 
a.m. following an overnight fast; a high carbohydrate breakfast 
(orange juice, 500 ml; whole wheat toast, 90 g; butter, 10 g; jam, 
20 g) was served at 7:45 a.m. At 8 a.m. the subjects ingested (with 
their juice) 24 capsules containing either 10.08 g APM or ATA. Hie 
subjects were also asked to complete the first of four VAS assessing 
subjective feelings of hunger, mood and arousal. At 9:30 a.m. (90 
min after capsule administration) a second blood sample was 
obtained. Hie remaining sets of VAS were completed at 10 a.m., 12 
noon and 2 p.m. 
To standardize protein intake during the trials, subjects were 
given portions of vanilla flavored Ensure (1.4 g protein/kg lean 
body mass; Ensure contains 14% protein, 31% fat, 54% carbohydrate, 
1.06 kcal/ml). Ensure allotments for each individual were divided 
into three equal meals at 12 noon, 4 p.m. and 8 p.m. Subjects had 
been instructed not to eat or drink anything, except tap water, 
between breakfast and the second blood sample. Individual energy 
requirements were met by consuming additional calories from apple 
juice, whole wheat bread and plain cake type doughnuts. 
Analytical Methods 
Plasma amino acid levels were determined fluorometrically by 
high pressure liquid chromatography (HPLC) following the method 
described by Femstrom and Fernstrom (1981). 
Statistical Analyses 
A one-way analysis of variance (ANOVA) with repeated measures 
was performed on food intake data from experiments 1 and 2 (Winer, 
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1971). Marks on the VAS were converted to numerical scores on which 
a two-way (treatment vs. time period) ANOVA with repeated measures 
was performed (Winer, 1971). Plasma amino acid levels were analyzed 
by paired t-tests (Steel & Torrie, 1980). 
CHAPTER IV 
RESULTS 
In experiment 1, the 13 subjects were (mean +_ S.D.) 24.2 
4.4 years of age, 177.7 + 4.1 cm in height, 68.7 +_ 5.9 kg in 
weight and 11.0 _+ 2.6 % body fat. Mean energy intakes did not 
differ significantly (Table 2). Macronutrient selection was not 
significantly different between feeding trials, but remained 
relatively constant at about 16% protein, 36% carbohydrate and 48% 
fat. Analysis of the VAS indicated that there were no treatment 
effects on stomach, head or general sensations or on degree of 
hunger or urge to eat (data not shown). 
Incremental changes from baseline plasma levels of PHE, TYR 
and the ratios of PHE, TYR and TOP to the other large neutral 
amino acids (NAA) are listed in Table 3. Plasma PHE levels were 
significantly increased (p < .05) at 5.04 g PHE (at 2.52 g PHE, 
the standard deviation was large and obscured statistical 
significance). Plasma TYR rose significantly (p < .05) at doses 
of 2.52 g HIE and 5.04 g PHE. Plasma PHE/NAA was significantly 
higher (p < .05) after all PHE doses, but plasma TYR/NAA was 
significantly increased (p < .05) only after doses of 2.52 g PHE 
and 5.04 g PHE. Plasma TOP/NAA was significantly lower (p < .05) 
following the 5.04 g PHE dose. 
Table 2 
Food Intake Following Phenylalanine (PHE) Administration in Mult Males 
Treatment 
Placebo PHE PHE PHE 
Food Intake 5.04 g AIAa 0.84 g 2.52 g 5.04 g 
Grams Consumed (dry wt.) 244.0 + 61.0 283.0 + 91.0 248.0 + 90.0 226.0 + 72.0 
Energy (kcal) 1330.0 + 311.0 1543.0 + 471.0 1334.0 + 479.0 1215.0 + 366.0 
Protein (%) 17.4 + 3.2 15.6 + 3.5 16.2 + 2.5 17.0 + 3.2 
Carbohydrate (%) 34.1 + 4.9 35.5 + 8.0 37.0 + 6.6 36.5 + 7.0 
FAT (%) 48.8 + 4.6 49.2 + 5.2 47.1 + 5.7 47.0 + 5.1 
CHOc/Protein (g/g) 2.1 + 0.7 2.5 + 1.1 2.4 + 0.6 2.3 + 0.9 
aALA = alanine. = 13, x i SD. CCHO = carbohydrate. 
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Table 3 
Changes in Plasma Amino Acid Concentrations and Ratios Following Phenylalanine (PHE) 
Administration in Adult Males 
Treatment 
Amino Acid Baseline Placebo PHE PHE PHE 
5.04 g ALA3 0.84 g 2.52 g 5.04 g 
PHE (ymoles/dl) 5, .4 ± 0 .7b -0. 36 + 0.58 3. 2 + 2, .4 10. 1 + 9.4 22 .4 + 7, 
* 
.2 
TYRC (umoles/dl) 6 .7 + 0 .9 -1. ,2 + 1.1 1. 5 + 3, .0 2. 7 + 
* 
2.2 3 .3 + 1, 
* 
.5 
d * * * 
PHE/NAA 0 .097 ± 0 .010 0, .005 + 0.01 0. ,065 + 0, .04 0, .174 + 0.13 0 .419 + 0 .14 
TYR/NAA 0 .123 ± 0 .012 -0. 004 + 0.02 -0. 026 + 0. 05 0. 029 + 0.02* 0 .016 + 0 
* 
.02 
TRPe/NAA 0 .123 ± 0 .005 0. 009 + 0.01 -0. ,008 + 0, .02 -0. 019 + 0.01 •0 .037 + 0 
* 
.02 
Note. The baseline shown is the average of the mean baselines for each individual which were calculated 
from the plasma values obtained prior to the four treatments. The treatment effects are shown as the 
differences between plasma values 45 min after treatment minus baseline values for that day's trial for 
each individual. 
aAIA = alanine. = 5, x i SD. CTYR = tyrosine. ^NAA = neutral amino acids. eTRP = tryptophan. 
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Different (p<0.05) from baseline, paired t-tests. 
For the five individuals who participated in the biochemical 
study, no consistent relationship existed between food intake and 
plasma amino acid levels. At the highest dose of PHE (5.04 g), 
plasma PHE increased more than 400% from baseline, and plasma TYR 
increased 60% from baseline. 
In experiment 2, the 13 subjects were (mean +_ S.D.) 23.1 ;+ 
3.8 years of age, 176.0 +_ 7.2 cm in height, 66.5 6.7 kg in 
weight, and 10.9 2.7 % body fat. Neither AHVI nor PHE affected 
mean energy intakes and macronutrient selection was not 
significantly different, but was similar to experiment 1 
(approximately 16% protein, 37% carbohydrate, 47% fat; Table 4). 
In spite of an absence of effect of PHE and AHVI on VAS scores in 
both these experiments, VAS scores were significantly changed (p < 
.05) over time (Figures 1 and 2). Before lunch, the subjects 
reported higher values for emptiness, stomach rumbling, weakness, 
degree of hunger and urge to eat; these effects of time were 
eliminated by eating lunch. No interactions were seen for any 
variable in either experiment. 
Oice again, no consistent relationships were found between 
food intake and plasma amino acid concentrations or ratios in 
those individuals from whcm blood was drawn. Values for plasma 
PHE, TYR, PHE/NAA, TYR/NAA and TRP/NAA are listed in Table 5. 
Plasma PHE concentration and its ratio to the other NAA rose 
significantly (p < .05) at all doses given (placebo excepted), but 
plasma TYR only rose (p < .05) at the highest dose of PHE (10.08 
Table 4 
Food Intake Following Phenylalanine (PHE) 
and Aspartame (APM) Administration in Adult Males 
Treatment 
Placebo APM APM PHE 
Food Intake 10.08 g ALAa 5.04 g 10.03 g 10.08 g 
Grams Consumed (drywt.) 226.0 + 63.0 203.0 + 57.0 207.0 + 66.0 197.0 + 69.0 
Energy (kcal) 1230.0 + 358.0 1103.0 + 355.0 1124.0 + 387.0 1070.0 + 385.0 
Protein (%) 16.7+ 3.2 16.5+ 3.6 15.6+ 3.3 16.1+ 4.0 
Carbohydrate (%) 35.8 + 5.4 37.5 + 7.2 38.1 + 7.0 36.7 + 5.5 
Fat (%) 47,7+ 4.2 46.1+ 6.1 46.6+ 6.2 47.3+ 3.5 
CHQC/Protein (g/g) 2.3+ 0^9 2.5+ 1.0 2.6+ 1.0 2.5+ 1.0 
aALA = alanine. = 13, x + SD. °CHO = carbohydrate. 
— CO 
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Figure 1. Mean VAS scores for three time periods in experiment 1 
illustrate the effect of lunch time on perceived feelings of hunger, 
mood and arousal. 
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Figure 2. Mean VAS scores for three time periods in experiment 2 
illustrate the effect of lunch time on perceived feelings of hunger, 
mood and arousal. 
Table 5 
Changes in Plasma Amino Acid Concentrations and Ratios Following Phenylalanine 
(PHE) and Aspartame (APM) Administration in Adult Males 
Treatment 
Amino Acid Baseline Placebo APM APM PHE 
10.08 g ALAa 5.04 g 10.08 g 10.08 g 
PHE (jjmoles/dl) 7 .1 + 0 .7b -1. 0 + 0 .6 5. 5 + 3 
* 
.9 19. 3 + 7. 
* 
8 76. 0 + 33. 
* 
1 
T¥RC (wnoles/dl) 7 .7 + 1 .2 0. 1 + 2 .5 2. 5 + 1, .5 4. 7 + 2. 9 8. 2 + 5. 
* 
4 
PHE/NAAd 0 .116 + 0 .013 0. ,017 + 0 .014 0. 083 + 0 .066* 0. 397 + 0. 204* 1. 261 + 0, .827* 
TXR/NAA 0 .129 + 0 .015 0. 012 + 0 .044 0. 032 + 0 .030 0, .065 + 0. 039* 0. 0 + 0. 051 
TRPe/NAA 0 .136 + 0 .028 -0. 014 + 0 .036 -0. 028 + 0 .020* -0. 046 + 0, .018* -0. 99 + 0, 
* 
.017 
Note. The baseline shown is the average of the mean baselines for each individual which were calculated 
from the plasma values obtained prior to the four treatments. The treatment effects are shown as the 
differences between plasma values 90 min after treatment minus baseline values for that day's trial for 
each individual. 
aALA = alanine. = 7, x + SD. CTYR = tyrosine. ^NAA = neutral amino acids. eTRP = tryptophan. 
* 
Different (p£ 0.05) from baseline, paired t-tests. 
g). The ratio of TYR to the other NAA increased significantly (p 
< .05) at a dose of 10.08 g APM, but the high plasma FHE levels at 
10.08 g FHE caused the plasma TYR/NAA to remain unchanged. 
HIP/NAA was significantly decreased (p < .05) at all doses except 
placebo. 
In experiment 3, the six subjects were (mean _+ S.D.) 26.7 
3.1 years of age, 173.6 4.8 cm in height, 68.3 7.0 kg in 
weight and 12.7 +_ 3.6 % body fat. Analysis of the VAS indicated 
that there were no treatment effects on stomach, head or general 
sensations or on degree of hunger or urge to eat (data not shown). 
However, the effects of time were observed for the variables 
emptiness, hunger and urge to eat. In the hours before lunch (10 
a.m. and 12 noon), the subjects rated these sensations higher than 
after lunch (Figure 3). No interactions were seen for any 
variable in this experiment. 
Plasma values for PHE, TYR, TRP, PHE/NAA, TYR/NAA and TOP/NAA 
are listed in Table 6. Comparisons are shown between the effect 
of a 10.08 g APM dose administered concurrently with a high 
carbohydrate (118 g) breakfast and the high carbohydrate breakfast 
alone (with placebo). The high carbohydrate breakfast caused a 
reduction (p < .05) in the plasma concentrations of PHE, TYR and 
TRP. Because the branched-chain amino acid levels were also 
reduced (Table 7), the ratio of FHE to the other NAA was increased 
(p < .05). However, the increases in TYR/NAA and TRP/NAA ratios 
did not reach significance. When APM was given with the high 
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Figure 3. Mean VAS scores for four time periods in experiment 3 
illustrate the effect of lunch time on perceived feelings of hunger* 
mood and arousal. 
Table 6 
Plasma Amino Acid Concentrations and Ratios Following Administration of Aspartame (APM) or Alanine (ALA) 
Placebo Concurrently With a High Carbohydrate Breakfast 
Experimental Condition 
Amino Acid Baseline APM (10.08 g) Baseline ALA (10.08 g) 
+ Breakfast + Breakfast 
PHE (pmoles/dl) 6. 4 + 1.1* 15. 3 + 5. 3 6. 8 + 0, .6 5. 9 + 0.9 
TYR (wnoles/dl) 8. 7 + 0.9 10, .7 + 3. 2 8. 6 + 1. 6 6. 5 + 
* 
1.3 
TRP (ymoles/dl) 7. 2 + 0.9 6. 7 + 1. 
* 
0 8. 0 + 1. 4 6. 3 + 
* 
1.5 
PHE/NAA 0. ,114 + 0.018 0. 303 + 0, .095* 0. 117 + 0. 026 0. 131 + 0.032* 
TYR/NAA 0. 169 + 0.050 0, .190 + 0. 032 0. 150 + 0, .036 0, .153 + 0.059 
TRP/NAA 0. 132 + 0.019 0, .116 + 0, .021 0. 137 + 0, .022 0, .139 + 0.023 
— 6/ x* + SD 
• 
Different (p<-05) from baseline, paired t-tests. 
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Table  7  
Pre-  and Post treatment  Branched-Chain  Amino  Acid  Leve l s  Fol lowing  a  
High  Carbohydrate  Breakfas t  and Aspartame (APM) Adminis trat ion  in  
Adul t  Males  
Treatment  
ALA a  Placebo  Plus  Breakfas t  APM^ P lus  Breakfas t  
Amino  Acid  Base l ine  Exper imenta l  Base l ine  Exper imenta l  
Val ine  20 .9  + 8 .0 C  17 .3  + 7 .5*  18 .8  + 7 .9  16 .6  + 7 .0  
(umoles /d l )  
Leuc ine  15 .8  + 2 .1  11 .3  + 2 .0*  14 .6  + 2 .2  11  . 4  + 1 .4*  
(umoles /d l )  
I so leuc ine  7 .7  + 0 .8  5 .6  + 1 .0*  7 .4  + 1  . 0  5 .9  + 0 .7*  
Curnol  e s /d l )  
a ALA = Alanine  
^APM =  Aspartame 
C N = 6 ,  x  +  S .D.  
*S igni f icant ly  <  0 .05)  d i f ferent  from base l ine .  
carbohydrate breakfast„ the plasma concentration of PHE increased 
(p < .05) significantly. Hcwever, the plasma TYR level did not 
significantly increase, primarily because of the large variation 
among subjects. The plasma level of TOP was significantly 
decreased (p < .05) following this treatment. The ratio of plasma 
FHE/NAA. was increased (p < .05), but the increase in the TYR/NAA 
ratio did not reach significance. The TOP/NAA ratio was not 
significantly decreased because of the large variation among the 
six subjects. 
DISCUSSICN 
Our results show that lunchtime energy intake and 
macronutrient selection were not affected by FHE or AB.1 in doses 
up to 10 g. In addition, subjective feelings of hunger, mood and 
arousal were unaffected by these doses. 
We chose the lunchtime feeding paradigm to assess the affect 
of HIE on food intake because it allows subjects to freely select 
from a variety of appealing foods, and provides a situation which 
allows a quantitative assessment of food consumption. Foods 
offered to the subjects were chosen for their lunch time appeal 
(i.e. sandwiches, cookies), but the high fat content (Table 1) of 
the cheeses, butter, salami and cookies with chocolate may have 
confounded preferences for protein or carbohydrate. Although no 
effects of WE and AIM were observed, this same feeding paradigm 
has been demonstrated to be appropriate in detecting effects of 
amino acids. TOP, the amino acid precursor for the brain 
neurotransmitter serotonin (Anderson et al., 1984), caused a 
significant (p < .001) reduction in energy consumption (250-400 
kcal) when two or 3 g TOP was given to lean, healthy adult males 
(Hrboticky, Leiter, & Anderson, 1985). Also, a greater 
suppression (p < .05) of carbohydrate food choices following TRP 
was observed in normal weight women, particularly women who were 
unrestrained eaters (Hrboticky, 1986). TRP has been shown to 
modulate behaviors such as sleep and mood (Leathwood & Pol let, 
1983; Lieberman et al., 1985). To provide subjective evaluation 
of hunger, mood and arousal, VAS are frequently used measures 
which correlate reasonably well with expressed behavior (IVlaxwell, 
1978). The scales appear to be sensitive to the effects of amino 
acids, if they occur, because administration of two or 3 g TRP 
produced mild psychotropic effects (increased drowsiness, 
increased dizziness and/or decreased mental alertness; p < .05) in 
normal weight men (Hrboticky et al., 1985). PHE and AFM did not 
affect the VAS, suggesting that if they did have mild psychotropic 
effects, these were much less robust than those of TRP and were 
undetectable by an assessment which has a large within subject 
variability. 
The lack of effect on VAS of large doses of AFM are of 
particular interest because of the Centers for Disease Control 
(CDC) report evaluating consumer complaints regarding AFM 
(Bradstock et al., 1986). The VAS used in our experiments 
contained descriptive words such as headache, dizziness, stomach 
ache, nausea, drowsiness, alertness and depression which are 
similar to those symptoms reported by complainants after AFM 
consumption in the CDC report. That none of our subjects reported 
any unusual reactions to APM consumption (in very high doses) may 
indicate that the symptoms noted by complainants were likely 
idiosyncratic and not representative of the general population. 
0 
Alternatively, these responses may be normal responses (see Figure 
1) to increasing energy (caloric) deprivation, which is 
self-inflicted and the reason many consumers choose APM containing 
beverages or foods. 
PHE administration by intragastric infusion has been shown 
to suppress food intake in rats (Anika, 1982), dogs (Meyer & 
Grossman, 1972), and monkeys (Gibbs et al., 1976). This appetite 
suppressing effect of PHE has been commonly attributed to the fact 
that PHE is a potent gut CJCK secretogogue (Walsh, 1981). Our data 
on PHE do not contradict the literature because the dose of PHE 
required to suppress food intake in Rhesus monkeys was 500 mg/kg 
body weight (Gibbs et al., 1976) and in rats, 1 g/kg body weight 
(Anika, 1982). In our experiments, the highest average WE dose 
was approximately 150 mg/kg body weight. Perhaps a much smaller 
endogenous OCK response than those used exogenously (Nicholl, 
Polak, & Bloom, 1985) accounts for the lack of effect of PHE on 
food consumption in men in the present study. In another human 
study, an amino acid mixture (PHE, 3 g; valine, 2 g; methionine, 2 
g; TRP, 1 g) preload produced short term satiety in four 
overweight subjects. Hie appetite suppression was attributed to a 
OCK mediated satiety by the authors (Butler, Davies, Gehling, & 
Grant, 1981). It seems more likely; however, that appetite 
suppression was mediated by TRP and valine which have been shown 
to suppress food intake in humans and rats, respectively 
(Hrboticky et al., 1985; Li et al., 1986). 
ALA was selected as a placebo in our experiments for two 
reasons. First, it does not stimulate the release of OCX (Walsh, 
1981), and second, it provides an equivalent source of nitrogen 
which, through the production of ammonia and urea, may influence 
food intake regulation centers (Ashley, 1974). To rule out this 
non-specific effect of amino acids and thus identify a unique role 
for an amino acid in influencing feeding behavior, ALA is a more 
appropriate control than a carbohydrate. By increasing the ALA 
placebo from 5.04 g in experiment 1 to 10.08 g in experiment 2, 
energy intake was not suppressed to any greater degree (1330 kcal 
vs. 1230 kcal); therefore our results also suggest that ALA, and 
the nitrogen it contains does not affect food intake. 
Biochemical measures such as plasma amino acid levels lend 
strong support to the interpretation of data arising from 
experiments in which behavioral testing is employed. Because the 
large neutral amino acids (NAA), primarily PHE, TYR, TRP, leucine, 
isoleucine, and valine, share a cannon carrier mechanism for 
uptake across the blood-brain-barrier (Pardridge, 1977), changes 
in plasma amino acid concentrations is an important factor in 
predicting precursor availability for brain neurotransmitter 
synthesis. Clearly, the doses of PHE and ATM led to changes in 
plasma FHE, TYR and amino acid ratios which would lead to 
increased brain uptake of PHE and TYR. In our experiments, 
administration of 5.04 g PHE resulted in a plasma PHE 
concentration of 27.7 fx moles/dl after 45 min, whereas 10.08 g 
AFM, which contains roughly 5 g fflE, resulted in a plasma PHE 
concentration of 26.2 ^moles/dl after 90 min. This suggests that 
plasma PHE levels do reach a peak by 45 min (e.g. as found in 
experiment 1) and are maintained for up to 90 min after capsule 
administration. Current views on precursor control of 
neurotransmitter synthesis suggest that alterations in brain 
neurotransmitter synthesis would be expected from the increased 
brain PHE and TYR (Sved, 1983). Clearly, if this occurred, no 
behavioral consequences were detected. 
The results of the VAS in experiment 3 were consistent with 
those of both experiments 1 and 2; only time had a significant 
effect on emptiness, hunger and urge to eat. The effects of time 
were expected and even the large within subject variability which 
is associated with VAS probably cannot obscure these effects. 
However, this large within subject variability may hinder the 
detection of more subtle effects of amino acids such as PHE, even 
when hunger, mood and arousal are assessed by VAS over a longer 
duration as conducted in experiment 3. However, the existence of 
any behavioral effects of PHE remains to be demonstrated. To this 
date, studies (Lieberman et al., 1985; Leathwood & Pollet, 1983) 
have been unable to demonstrate any behavioral effects of TYR in 
humans, and PHE would be expected to function in a similar fashion 
as TYR. 
Blundell and Hill (1986) reported that although consumption 
of an AFM sweetened solution (162 mg in 200 ml) resulted in a 
depression of the perceived pleasantness of 10 samples of 20% 
sucrose. Appetite motivation (hunger, desire to eat) was not 
suppressed and ratings of fullness were decreased compared to a 
glucose load (50 g in 200 ml) of equivalent sweetness. These 
results are not unexpected; the energy deficit created by the 
ingestion of APM sweetened beverages may indeed increase hunger 
and urge to eat when compared with calorie containing sugar 
solutions. The popularly held view that artificial sweeteners 
provide the sensory pleasure and satisfaction of hunger that sugar 
provides, but without calories, was first demonstrated to be 
untrue by Hausmann (1933). Rats preferred glucose and saccharin 
solutions to water, but only when the rats drank sugar solutions 
did they reduce their solid food intake. That significant 
differences in appetite motivation were observed between AFM and 
water loaded volunteers, except when testing was done on 
volunteers who fasted for 4 hr in the Blundell and Hill experiment 
has not been observed before; therefore, this aspect should be 
explored more thoroughly. Certainly, in o\ir experiment when APM 
was uncoupled from its sweet taste by administering it in capsule 
form and the subjects were allowed to eat (there were no 
differences in energy consumption between the two trials), there 
were no differences in hunger or urge to eat between AFM and the 
ALA placebo (20 +_ 19 APM vs 23 4^ 22 ALA, hunger; 17 +_ 20 AFM vs 23 
+_ ALA, urge to eat). 
Comparing the effects on plasma amino acids of a high 
carbohydrate breakfast alone vs. AEVJ plus a high carbohydrate 
breakfast provides useful data because of the suggestion that AHVI 
plus carbohydrate will influence behavioral mechanisms mediated by 
catecholamines (Coulombe & Sharma, 1986; Yokogoshi et al.y 1984). 
In a preliminary experiment with humans, Yokogoshi et al . (1984) 
reported that plasma PHE and TYR ratios were elevated beyond the 
normal ranges in six healthy subjects following ingestion of APM 
(15 mg/kg) with a snack providing 200 g of carbohydrate. For a 70 
kg male, the AFM dose is roughly equivalent to 1 g; in our 
experiment, we gave a dose of approximately 10 g. 
The reduction in branched-chain amino acids (Table 7) 
following the administration of carbohydrate is related to the 
secretion of insulin which enhances the uptake of branched-chain 
amino acids by muscle. PHE and TYR are also taken up by 
peripheral tissues for the same reason, but TRP is generally 
protected from peripheral uptake because it is bound to albumin 
(Anderson et al., 1984). Plasma PHE and TYR may be reduced in 
experiment 3 after a high carbohydrate meal because of peripheral 
or central uptake, but it is likely that, after 90 min, plasma TRP 
is reduced because of enhanced brain uptake. When AFM was 
administered with the high carbohydrate breakfast, the absolute 
and relative concentrations of PHE increase as expected. However, 
of special significance is that the administration of 10.08 g APM 
caused a .19 millimolar rise in plasma PHE after 90 min (6.9 +1.2 
pmoles/dl to 26.2 +_ 7.8 pmoles/dl) in experiment 2, hut when 10.08 
g APM was administered concurrently with cai-bohydrate, a rise of 
only .09 millimoles in plasma PHE (6.4 +_ 1.1 pmoles/dl to 15.3 +_ 
5.3 pmoles/dl) was observed after 90 min. Although some PHE may 
have been taken up by the brain, it is also likely that the rise 
in insulin due to carbohydrate ingestion may have resulted in 
peripheral uptake and oxidation of PHE. 
Notably, the absolute and relative concentrations of TYR did 
not increase when APM was given with the high carbohydrate 
breakfast. The conversion of PHE to TYR varies considerably 
among subjects and may be influenced by the individual's needs for 
PHE and TYR, both essential amino acids. 
The reduction in plasma TRP may still be caused by brain 
uptake, but it must be noted that the TOP/N^ ratio is not 
necessarily favorable (mean = 0.132 baseline vs. mean = 0.116 at 
90 min) to brain uptake because of the high plasma PHE levels (6.4 
;+ 1.1 pmoles/dl baseline vs. 15.3 +_ 5.3 pmoles/dl at 90 min). In 
addition, if both PHE and TRP are taken up by the brain, then 
synthesis of both catecholamines and serotonin might be expected. 
Ihese neurotransmitters have been demonstrated to have conflicting 
influences on feeding behavior in animals (Liebowitz, 1984). Ihe 
changes in plasma PHE, TYR, TRP and their ratios to the other 
large NAA are dependent on two factors: 1) the decline of 
branched-chain amino acids due to insulin secretion following 
carbohydrate consumption and 2) the appearance of PHE and TYR in 
plasma due to AM consumption. Overall, individual differences 
among subjects' responses to both AFM consurption and/or ingestion 
of carbohydrate may be related to gastrointestinal transit timey 
insulin release and the speed at which enzymatic conversion of PHE 
to TVR takes place. 
CHAPTER VI 
SlMVtARY 
In conclusion, both fflE and AIM in doses up to 10 g failed 
to alter food intake or hunger, mood and arousal in normal weight 
adult males, even though significant changes in the absolute and 
relative concentrations of plasma HIE and TYR were observed. Ihe 
highest PHE load was greater than two times the usual daily intake 
(National Research Council, 1974), and the highest AIM load 
approximates that present in 70-100 cans of soft drink containing 
this sweetener. 
Further research is necessary to determine if the failure of 
these amounts to alter behavior was due to an inability of FHE and 
ATM to alter neurotransmitter synthesis, or if neurochemical 
effects were counteracted by the multiplicity of control systems 
which regulate behaviors in humans. 1\vo recommendations for 
further research are to measura urinary catecholamine metabolites 
as an indicator of neurotransmitter synthesis and to conduct 
long-term studies with PHE and AIM. 
The measurement of urinary catecholamine metabolites, which 
partially reflect CNS activity (Johnston et al., 1983), shotild be 
included in future experiments. Because PHE had no effect on 
behavior in the current experiments, the possibility that urinary 
metabolites were unchanged exists. However, even if urinary 
catecholamine metabolites are found to respond to these large 
doses, one should remember that feeding behavior may be controlled 
by several brain monoamine and neuropeptide systems whose actions 
vary depending on what brain regions and/or receptor sites are 
affected (Leibowitz, 1986; Anderson et al.„ 1984). 
The approaches used in the experiments reported herein may 
not qualitatively assess the interactions among neurotransmitter 
precursors and the multiple neurochemical systems regulating food 
intake, hunger, mood and arousal under usual conditions. 
Detection of subtle responses to PHE and AFM, if they occur, will 
be difficult. Because short-term studies may be unable to detect 
subtle changes, the need for long-term studies is apparent. 
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University of Toronto 
Department of Nutritional Sciences 
University of Toronto 
Informed Consent 
A research study related to the role of dietary supplements in 
taste perception, has been explained to me and I have been asked to 
participate. I understand that I will be required to participate in up 
to five experimental sessions. These sessions will consist of: 
1. an orientation session during which dietary, demographic, 
health and anthropometric (height, weight, triceps, biceps, 
subscapular and suprailiac skinfolds) data will be obtained. 
2. four sessions which will involve the following protocol 
(i) eating a standardized breakfast, after an overnight 
fast, provided by the research team (arrival at 8:30 
a.m.) 
(ii) taste evaluation of several food samples, before and 
after administration of a dietary supplement obtained 
from normal food sources (10 a.m.) (Sweeteners, Amino 
Acids). 
(iii) a buffet style luncheon, followed by a final taste 
evaluation (12 noon). 
Each test session will be approximately 2 hours in duration, excluding 
breakfast. 
In addition, I agree, if selected, to provide a blood sample during each 
of the 5 sessions. The blood (20 ml, equivalent to 4 teaspoons) will be 
drawn from a vein in my arm. Blood drawing procedures may result in 
possible slight discomfort and bruising from the venepuncture, but I am 
aware that the risk involved is equivalent to that of giving a routine 
blood sample. 
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Informed Consent (cont'd) 
I am aware that the following conditions will prevail at all times. 
1. My participation will not involve any health risk or 
discomfort. 
2„ All personal information given by me will remain confidential 
and my name will not appear in any publication. 
3. I may withdraw from the study at any time without prejudice. 
I also understand that it is hoped that I shall take part in the full 
series of sessions, and that unless I complete all sessions, my efforts 
will be of little use to the researchers. 
Upon completion of the 5 sessions, I will receive financial compensation 
of $50. 
Results of the stu.dy will be made available to me upon completion of the 
experiment; if I have any questions I should contact Milly Ryan-Harshman 
in the Department of Nutritional Sciences (978-6394). 
I hereby agree to participate in the study. 
Date Participant's signature 
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University of Toronto 
Department of Nutritional Sciences 
Informed Consent 
A research study related to phenylalanine and its effect on behaviour has 
been explained to me and I have been asked to participate. I understand 
that I will be required to participate in two experimental sessions. 
The protocol for the two sessions is as follows: 
1) consumption of either phenylalanine, as aspartame, or placebo 
(10 g) in capsules at 8 a.m. (breakfast served at 7:45 a.m.). 
2) completion of visual analog scales which assess subjective 
mood, hunger and arousal at 8 & 10 a.m., noon and 2 p.m.. 
3) participate in five consecutive urine collection periods 
(8 a.m. to 12 p.m., 12 p.m. to 4 p.m., 4 p.m. to 8 p.m., 
8 p.m. to 12 a.m., and 12 a.m. to 8 a.m.). 
4) meals will be provided by the researcher in the form of 
Ensure. 
In addition, I agree to provide a blood sample at 7:30 a.m. and 9:30 a.m. 
during each of the sessions. The blood (20 ml, equivalent to 4 tea­
spoons) will be drawn from a vein in my arm. Blood drawing procedures 
may result in possible slight discomfort and bruising from venepuncture, 
but I am aware that the risk involved is equivalent to that of giving a 
routine blood sample. 
I am aware that the following conditions will prevail at all times. 
1) My participation will not involve any health risk or 
discomfort. 
2) All personal information given by me will remain confidential 
and my name will not appear in any publications. 
3) I may withdraw from the study at any time without prejudice. 
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INFORMED CONSENT (cont'd) 
Results of the study will be made available to me upon cotpletion of the 
experiment; if I have any questions I. should contact Milly Ryan-
Harshman in the Department of Nutritional Sciences (978-6894). 
I hereby agree to participate in this study. 
Date Participant's Signature 
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Date: 
Name: 
Address: 
Date of Birth: 
Place of Birth: 
Sex: Height: Weight: 
Occupation: 
If student, field of study: 
Highest education level reached: 
Marital Status: 
Subject ID 
Demographic and Health Information 
Telephone: 
How would you describe your present weight? 
O underweight 
normal weight 
O moderately overweight 
O very overweight 
What was your weight at these periods in your life? 
Normal Moderately Very 
Age Weight Overweight Overweight 
0-6 o o o preschool V-/ >—/ V—' 
1-12 
childhood o o o 
4 
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Demographic and Health Information (cont'd) 
2.(cont'd) Normal Moderately Very 
Age Waight Overweight Overweight 
13-15 
early teens 
16-19 
late teens 
20-29 
30-39 
O O O 
O o o 
o o o 
o o o 
3. Has your weight varied fron your present weight in the last 5 
years? 
If yes, when 
If yes, number of pounds 
4. Have you ever attempted to lose weight? 
YES 
NO 
gain weight? YES 
NO 
5. Are you presently attempting to lose weight? 
YES NO 
How: 
gain weight: YES NO 
How: 
Demographic and Health Information (cont'd) 
6. How would you describe your father's weight? 
underweight 
normal weight 
moderately overweight 
very overweight 
7. How would you describe your mother's weight? 
underweight 
normal weight 
moderately overweight 
very overweight 
8. Any of your siblings (brothers, sisters) overweight? 
YES NO NO SIBLINGS 
Specify: 
9. Do you have any of the following health problems? 
diabetes 
high blood pressure 
thyroid disorder 
loss of appetite 
poor sense of smell 
Others? 
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Demographic and Health Information (cont'd) 
10. Are you presently taking any medications on a daily or weekly 
basis? 
YES NO 
Type: 
Dose: Frequency: 
11. Are you presently taking vitamin and/or mineral supplements? 
YES NO 
Type1 
Dose: Frequency: 
12. Do you consider yourself to be: 
O extremely athletic 
moderately athletic 
O slightly athletic 
(̂ ) not athletic 
13. Which of the following health problems has your father had? 
Check the appropriate boxes. 
• diabetes 
• high blood pressure 
• stroke 
• angina (chest pain) 
• heart attack before age 50 
• other heart or artery problems 
describe 
Demographic and Health Information (cont'd) 
13. (cont'd) • phlebitis 
• other vein problems 
describe 
• gout 
• gall bladder disease-
• goitre 
• other thyroid problems 
describe 
• arthritis 
14. Which of the following health problems has your mother had? 
Please check the appropriate boxes. 
• diabetes 
• high blood pressure 
• stroke 
• angina (chest pain) 
• heart attack before age 50 
• other heart or artery problems 
describe 
• phlebitis 
• other vein problems 
describe 
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Demographic and Health Information (cont'd) 
14.(cont'd) • gout 
• gall bladder disease 
• goitre 
• other thyroid problems 
describe 
• arthritis 
15. Are you presently following any dietary restriction for medical, 
religious or personal reasons? 
(e.g., vegetarianism). 
YES NO 
Specify: 
16. Do you suffer from any food allergies? 
YES NO 
Specify: 
17. Do you suffer from any food intolerances? 
YES NO 
Specify: 
18. How many times a week do you eat? 
0 12 
breakfast 
mid-morning snack 
lunch 
afternoon snack 
dinner 
evening snack 
Demographic and Health Information (cont'd) 
19. Describe your typical 
Breakfast: 
Lunch: 
Dinner: 
20. Do you smoke? 
YES NO 
APPENDIX C 
EATING HABITS QUESTIONNAIRE 
80 
Eating Habits Questionnaire 
Date: 
Name: 
I.D.: 
The following questions refer to your normal eating pattern and weight 
fluctuations. Please answer accordingly. 
1. How often are you dieting? (Circle one) 
Never Rarely Sometimes Usually Always 
2. What is the maximum amount of weight (in pounds) you have ever lost 
within one month? (Circle one) 
0-4 5-9 10-14 ' 15-19 20+ 
3. What is your maximum weight gain within a week? (Circle one) 
0-1 1.1-2 2.1-3 3.1-5 5.1+ 
4. In a typical week, how much does your weight fluctuate? (Circle 
one) 
0-1 1.1-2 2.1-3 3.1-5 5.1+ 
5. Would a weight fluctuation of 5 lbs. affect the way you live your 
life? (Circle one) 
Not at all Slightly Moderately Very much 
6. Do you eat sensibly in front of others and splurge alone? 
(Circle one) 
Never Rarely Often Always 
7. Do you give too much time and thought to food? (Circle one) 
Never Rarely Often Always 
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Eating Habits Questionnaire (cont'd) 
8. Do you have feelings of guilt after overeating? (Circle one) 
Never Rarely Often Always 
9. How conscious are you of what you're eating? (Circle one) 
Not at all Slightly Moderately Extremely 
10. What was your maximum weight ever? 
11. How many pounds over your desired weight were you at your maximum 
weight? 
0-1 1-5 6-10 11-20 21+ 
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APPENDIX E 
HUNGER QUESTIONNAIRE 
86 
Hunger Questionnaire 
Date: Time: Subject ID: 
This questionnaire contains several sensations related to hunger. 
Please evaluate your present feelings on the horizontal scales below: 
I. Stomach sensations 
1. emptiness 
none at all extreme 
2. rumbling 
3. ache 
none at all extreme 
4. nausea 
none at all extreme 
none at all extreme 
Head sensations 
5. headache 
6. dizziness 
none at all extreme 
7. faintness 
none at all extreme 
none at all extreme 
General sensations 
8. drowsy 
9. weak 
not at all extremely 
10. nervous 
not at all extremely 
not at all extremely 
87 
Hunger Questionnaire (continued) 
11. tense 
12. drugged 
not at all extremely 
13. depressed 
not at all extremely 
14. alert 
not at all extremely 
15. mentally slow 
not at all extremely 
not at all extremely 
Are you experiencing any other sensations not described by the 
scales? If yes, please describe: 
V. How hungry are you? 
not at all as hungry as you 
have ever felt 
Describe your urge to eat: 
no large to eat very strong 
urge to eat 
APPENDIX F 
RAW DATA 
ID 
101 
102 
103 
104 
105 
106 
107 
108 
109 
1 1 0  
111 
112 
113 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112  
113 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
1 1 2  
113 
89 
Energy Intakes (kcal)  
Experiment 1 
Placebo 
5.04 g ALA 0.84 g PHE 2.  52 g PHE 5.04 g PHE 
1420 1353 1786 1242 
1036 1245 1274 1043 
782 898 904 538 
1422 1371 1360 1266 
1078 1499 1449 985 
1744 2735 2123 1662 
1385 1949 1707 936 
1115 1160 823 1152 
2081 1912 1912 2036 
1295 1307 1427 1016 
1327 .. 1316 671 1391 
1334 1266 1551 972 
1272 2050 484 1549 
Protein Intakes (%) 
Experiment 1 
14.7 10.0 14.1 15.7 
15.3 15.0 13.5 15.0 
20.0 15.0 20.2 19.6 
16.0 17.0 17.1 19.9 
20.5 20.2 17.4 18.5 
19.0 18.5 ' 18.4 17.8 
18.3 17.4 14.3 16.2 
23.5 21.4 16.6 23.6 
11.5 12.2 13.1 11.3 
15.3 14.1 13.0 15.6 
14.4 13.4 15.9 17.0 
16.4 9.9 15.9 12.0 
21.0 18.0 20.7 19.1 
Carbohydrate Intakes (%) 
Experiment 1 
36.4 43.7 37.3 36.4 
39.5 39.0 41.5 41.9 
28.6 34.1 22.3 31.3 
33.8 30.3 34.0 36.5 
27.6 28.1 27.0 31.8 
37.0 32.1 38.7 36.5 
34.3 33.4 40.4 40.5 
33.2 19.3 44.5 30.3 
46.6 48.8 44.8 49.0 
28.8 29.5 36.1 30.2 
31.0 35.6 43.3 26.5 
32.0 48.1 30.3 50.7 
34.5 39.1 39.8 36.4 
ID 
ToT 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
101 
102 
103 
104 
105 
106 
107 
108 
109 
1 1 0  
111 
112 
113 
90 
Fat Intakes (%) 
Experiment 1 
icebo 
i g  ALA 0.84 g PHE 2.  52 g PHE 5.04 g PHE 
49.7 46.5 49.5 49.1 
45.2 46.3 45.1 43.0 
51.5 51.2 57.7 50.0 
50.6 53.0 49.3 47.3 
52.3 52.3 56.1 50.1 
44.4 50.2 43.6 46.3 
48.2 50.1 46.6 44.7 
43.5 59.4 39.0 46.6 
40.7 40.0 42.9 40.5 
56.1 54.0 50.2 54.2 
55.3 51.7 41.8 57.0 
52.4 42.1 51.5 37.6 
44.4 42.9 39.1 44.3 
Carbohydrate/Protein Intakes (.%) 
Experiment 1 
2 .5 4.4 2.7 2.3 
2.6 2.6 3.1 2.8 
1.4 2.3 1.1 1.6 
2.1 1.8 2.0 1.7 
1.4 1.4 1.6 1.7 
1.9 1.7 2.1 2.1 
1.9 1.9 2.8 2.5 
1.4 0.9 2.7 1.3 
4.0 4.0 3.4 4.3 
1.9 2.1 2.8 1.9 
2.1 2.7 2.7 1.6 
2.0 4.9 1.9 4.2 
1.7 2.2 1.9 1.9 
Total  Food Consumed (dry wt •» 9)  
Experiment 1 
260 252 327 229 
194 232 239 198 
140 161 154 98 
257 243 248 234 
192 268 251 179 
331 498 406 311 
256 356 322 179 
212 195 161 215 
396 376 368 399 
224 221 255 178 
231 237 130 239 
239 243 268 193 
239 390 94 291 
Plasma Amino Acid Levels  (umoles/dl)  
Experiment 1 
ID ALA TYR VAL ILE TRP LEU PHE 
Placebo (5.04 q ALA) 
Basel  ine 
101 57.5 10.7 34.6 10.8 14.5 16.8 9.6 
105 36.6 6.9 22.2 7.8 11.5 12.3 7.2 
109 37.7 7.0 22.4 6.3 10.2 12.1 7.9 
111 40.0 10.3 21.9 6.6 7.9 12.4 6.4 
113 37.6 6.3 23.9 5.3 9.2 9.7 7.0 
Experimental  
101 61.3 7.9 29.8 7.9 10.0 14.1 6.2 
105 58.4 5.7 23.4 6.4 10.6 11.7 6.1 
109 48.4 7.1 22.6 5.8 9.5 9.8 6.7 
111 65.7 8.6 18.4 5.3 7.4 10.5 5.8 
113 59.7 7.1 23.1 5.6 10.9 10.7 6.9 
0.84 q PHE 
Baseline 
101 79.0 9.7 27.5 9.5 8.5 20.5 7.8 
105 39.9 5.3 25.5 6.6 6.9 14.8 6.4 
109 42.4 6.4 22.6 5.9 8.6 13.3 6.0 
111 39.2 8.6 20.4 5.9 7.0 11.7 5.8 
113 41.1 6.5 19.4 5.9 7.1 12.9 6.1 
Experimental  
101 102.7 9.5 25.0 8.3 9.1 17.6 9.7 
105 54.8 6.7 25.6 6.1 6.9 16.0 7.3 
109 58.9 9.2 20.3 7.1 7.7 14.2 9.8 
111 63.4 10.3 20.4 5.3 6.6 11.1 10.9 
113 50.0 6.5 17.1 4.8 6.2 8.9 7.1 
2.52 q PHE 
Baseline 
101 69.0 8.5 27.1 8.6 9.6 18.6 7.6 
105 52.2 7.0 24.5 7.2 7.7 15.9 6.3 
109 27.5 6.8 18.9 5.8 6.2 13.9 6.8 
111 45.8 8.5 18.7 5.6 7.4 9.9 6.1 
113 45.1 7.3 21.6 6.5 8.2 14.1 7.7 
92 
ID ALA TYR VAL ILE TRP LEU PHE 
Experimental  
101 82.7 13.0 29.0 8.3 9.3 18.4 37.5 
105 63.6 8.2 23.6 6.7 6.7 15.5 11 .7  
109 30.1 9.2 19.0 5.8 7.2 14.1 15.2 
111 56.7 10.4 21.4 5.2 7.7 10.2 15.9 
113 43.1 7.9 18.7 4.0 5.7 11.6 8.0 
5.04 q PHE 
Baseline 
101 64.5 10.0 26.5 9.2 9.7 17.8 7.8 
105 59.2 8.9 25.7 6.4 8.0 15.8 5.9 
109 27.6 5.8 17.4 4.5 7.3 11 .1 5.9 
111 34.2 7.6 19.9 5.9 6.8 12.4 6.8 
113 35.8 7.1 17.6 4.5 7.0 11 .3  5.5 
Experimental  
101 53.5 12.9 24.5 7.5 9.1 14.8 30.7 
105 57.4 13.3 23.1 6.8 7.7 14.5 28.5 
109 28.2 12.9 17.6 5.0 7.5 11.5 38.3 
111 39.3 9.2 21.4 5.9 7.6 12.0 22.8 
113 33.7 10.3 18.7 4.7 6.8 11.1 14.3 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
2 
3 
3 
3 
93 
Visual Analog Scale Scores 
Experiment 1 
Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
1 41 16 00 00 01 19 01 02 12 01 01 26 02 45 18 41 26 
2 72 45 01 01 01 24 01 01 15 27 26 01 01 24 01 58 45 
3 01 01 01 01 01 01 01 29 01 01 14 01 01 59 19 01 14 
1 42 30 01 01 44 01 01 50 18 01 01 01 21 34 21 44 39 
2 28 16 06 01 18 22 00 59 16 00 00 24 00 31 60 41 36 
3 01 00 00 00 00 12 13 33 00 00 00 00 00 46 27 01 01 
1 35 20 12 01 01 01 01 16 01 01 01 01 01 32 35 51 56 
2 60 14 28 00 00 00 01 01 16 01 01 01 01 57 01 55 38 
3 01 01 01 01 01 02 01 33 01 01 01 01 01 46 01 01 02 
1 29 08 44 01 01 01 02 01 01 01 01 01 01 72 01 43 37 
2 52 00 11 00 01 22 10 08 00 00 00 00 00 48 14 42 43 
3 00 00 00 00 00 11 00 00 00 00 00 00 00 43 06 05 00 
1 29 00 00 00 00 05 00 00 12 00 00 00 00 48 00 59 59 
2 53 16 00 00 00 09 00 08 09 00 00 00 00 49 00 61 65 
3 00 00 00 00 00 00 00 10 00 00 00 00 00 45 00 00 00 
1 60 37 00 00 16 17 38 39 29 19 20 00 00 53 11 58 62 
2 56 10 10 01 23 23 23 22 15 00 00 00 00 39 09 62 65 
3 00 00 00 00 06 00 00 05 00 00 00 00 00 55 00 04 00 
1 54 00 00 00 00 19 00 00 19 00 00 00 00 41 41 62 65 
2 65 00 00 00 15 15 00 00 13 00 00 00 00 50 50 66 68 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 45 46 04 04 
1 35 00 00 00 00 00 10 00 00 00 00 00 00 50 00 46 48 
2 53 00 05 00 08 00 00 11 12 00 00 00 00 51 00 69 70 
3 00 00 00 00 00 00 00 05 00 00 00 00 00 52 00 00 00 
1 37 18 19 05 12 10 09 61 13 12 13 12 30 55 34 26 22 
2 55 47 15 18 50 35 07 61 16 14 14 15 25 45 44 62 57 
3 10 09 12 10 13 10 11 27 12 10 10 12 17 56 24 88 15 
1 39 04 04 01 02 02 35 65 04 06 67 04 51 51 09 62 51 
2 63 55 19 12 10 17 03 65 15 04 58 05 51 37 53 45 50 
3 08 06 06 07 06 25 04 51 06 05 48 05 48 48 06 14 15 
1 20 20 03 03 03 28 04 60 22 04 03 03 24 28 38 47 34 
2 35 26 05 04 06 14 11 39 16 05 07 07 28 47 33 57 48 
3 08 08 08 08 12 34 05 32 07 08 10 10 17 58 49 16 08 
I 18 17 18 18 10 09 09 42 07 08 08 08 22 63 60 22 30 
2 55 41 36 15 16 14 11 53 08 08 08 09 10 51 50 60 62 
3 12 11 11 10 19 19 18 39 13 15 11 09 10 74 12 09 13 
1 62 37 07 18 00 04 12 45 06 00 00 00 00 50 25 76 82 
2 73 10 00 00 00 00 05 55 07 00 00 00 00 60 12 81 87 
3 00 00 00 00 00 00 00 36 19 00 00 00 00 64 17 00 08 
1 26 09 00 00 00 00 00 42 00 00 00 00 33 63 12 33 45 
2 38 19 00 00 16 00 00 39 13 00 00 00 05 64 51 52 63 
3 00 00 00 00 00 00 00 37 00 00 00 00 00 69 17 00 05 
1 36 06 00 00 10 00 00 26 00 13 13 00 00 69 00 55 43 
2 42 16 00 00 09 00 00 48 09 02 00 00 00 59 08 56 38 
3 00 00 00 05 04 00 00 07 12 00 00 00 00 63 04 00 10 
94 
ID 
ToT 
105 
106 
107 
108 
Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
4 1 50 21 00 00 45 39 05 79 £9 00 00 00 00 44 61 66 45 
4 2 52 11 00 00 21 19 00 40 27 00 00 00 00 41 55 55 70 
4 3 00 00 00 00 24 00 00 19 15 00 00 00 00 66 30 00 05 
1 1 62 01 01 01 01 01 01 10 04 00 00 00 04 81 03 62 64 
1 2 76 72 02 02 02 02 02 03 03 03 03 03 03 83 04 71 74 
1 3  08 01 01 01 01 01 01 01 01 01 01 01 01 88 05 02 02 
2 1 29 01 02 02 01 03 02 02 02 02 02 02 02 83 02 65 67 
2 2 82 01 08 01 04 04 03 02 09 02 03 04 02 76 04 82 83 
2 3 03 00 00 00 00 00 00 01 • 00 00 00 00 00 91 01 02 02 
3 1 26 00 00 00 00 00 00 04 00 00 00 00 00 79 16 52 54 
3 2 71 01 01 01 00 00 00 01 02 01 02 01 01 83 13 76 75 
3 3 05 01 01 01 00 00 01 00 00 00 00 00 00 88 07 02 03 
4 1 68 13 01 01 01 01 01 08 13 02 03 01 02 71 10 68 71 
4 2 76 17 18 20 27 36 26 61 11 02 02 58 02 73 06 76 79 
4 3 08 01 01 01 01 01 01 01 01 04 01 01 01 90 03 06 09 
1 1 33 04 02 01 35 02 05 76 64 22 45 19 35 25 64 34 43 
1 2 69 25 16 13 51 30 14 54 44 40 52 23 34 42 48 67 73 
1 3 01 00 00 00 00 00 00 16 05 01 03 01 04 59 59 07 03 
2 1 33 04 04 03 06 08 02 33 09 01 08 02 03 49 22 49 37 
2 2 52 20 10 05 14 08 07 29 27 10 02 02 02 48 31 57 62 
2 3 00 00 16 00 00 02 04 12 00 00 00 00 00 60 29 02 02 
3 1 52 09 08 01 25 29 08 67 56 11 16 09 12 45 45 59 47 
3 2 63 11 15 03 36 38 26 64 44 07 11 07 25 27 58 63 50 
3 3 03 00 00 00 13 00 00 05 02 00 00 00 03 75 06 33 53 
4 1 29 02 02 01 02 24 18 28 11 05 06 02 20 41 39 41 30 
4 2 46 06 08 00 38 20 16 15 20 08 03 02 22 47 31 38 32 
4 3 07 00 00 00 00 01 01 47 15 01 01 01 06 69 19 04 03 
1 1 68 41 38 32 06 05 06 06 08 07 07 06 06 94 02 47 53 
1 2 79 67 53 34 04 03 02 22 18 16 20 24 06 31 50 93 83 
1 3  02 13 13 09 06 26 24 35 33 15 15 18 13 75 07 02 01 
2 1 65 08 09 10 11 17 11 11 10 10 10 09 08 07 06 30 35 
2 2 68 40 21 15 11 10 07 11 15 11 09 24 07 87 06 75 73 
2 3 02 02 02 03 03 03 03 05 05 05 07 03 05 93 02 02 03 
3 1 77 19 17 08 04 04 03 05 05 04 06 06 05 87 03 69 63 
3 2 97 21 30 05 02 00 01 02 05 02 02 03 04 96 02 80 82 
3 3 03 04 02 03 04 04 08 06 05 04 04 03 04 00 00 03 04 
4 1 54 59 53 04 03 00 04 09 05 05 04 05 04 87 05 38 49 
4 2 79 41 45 43 04 03 03 07 07 06 06 05 05 90 04 75 84 
4 3 02 02 03 03 03 02 01 05 05 04 04 04 04 97 03 03 03 
1 1 52 22 22 26 10 34 33 17 24 30 40 21 20 62 22 29 28 
1 2 55 26 21 22 19 19 33 20 21 22 32 32 22 63 16 55 34 
1 3 13 13 15 18 12 11 09 09 09 09 15 12 10 41 31 27 09 
2 1 73 56 15 19 20 23 58 12 56 14 14 17 15 79 12 59 50 
2 2 80 66 11 11 13 27 52 15 29 13 12 11 10 85 10 72 65 
2 3 40 24 06 05 07 06 08 10 21 11 09 09 08 71 18 38 08 
95 
ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
T08 3 1 21 18 19 16 07 06 07 33 14 10 09 08 10 55 20 17 21 
3 2 28 09 08 09 12 10 08 24 20 07 06 06 06 49 17 22 28 
3 3 17 13 12 14 14 18 08 11 09 10 13 10 10 65 15 17 14 
4 1 73 16 18 22 13 33 31 26 32 09 44 10 38 59 16 67 65 
4 2 74 14 16 19 11 37 36 24 29 11 29 20 35 70 24 76 63 
4 3 34 06 06 07 15 14 14 21 15 16 25 17 28 66 23 34 37 
109 1 1 65 01 13 01 00 00 00 00 00 00 00 00 00 83 19 55 68 
1 2  71 00 14 00 00 00 00 00 00 00 00 00 00 80 19 78 79 
1 3  00 00 00 00 00 00 00 00 00 00 00 00 00 83 14 00 00 
2 1 68 00 50 00 13 00 00 00 00 00 00 00 00 84 13 74 78 
2 2 83 00 16 00 01 01 01 00 00 00 00 00 00 00 00 76 75 
2 3 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 
3 1 64 00 00 00 00 00 00 29 00 00 00 00 00 62 07 62 68 
'3  2 73 00 00 00 00 00 00 00 00 00 00 00 00 00 00 69 72 
3 3 00 00 02 02 00 00 00 00 00 00 00 00 00 85 13 11 00 
4 1 60 00 00 00 00 00 00 00 00 00 00 00 00 74 21 65 70 
4 2 68 01 01 01 00 00 00 00 00 00 00 00 00 00 00 67 63 
4 3 00 00 00 00 00 CO 00 00 00 00 00 00 00 88 14 00 00 
110 1 1 50 10 10 10 00 00 00 00 00 00 00 00 00 00 00 54 48 
1 2  19 18 36 18 10 00 10 00 00 00 00 00 00 00 51 69 69 
1 3 11 00 00 00 00 00 00 00 00 00 00 00 00 00 00 07 00 
2 1 64 27 48 03 00 00 00 00 00 00 00 00 00 00 20 65 50 
2 2 72 13 13 05 07 08 08 00 00 00 00 00 00 00 64 72 63 
2 3 87 07 00 00 00 00 00 00 00 00 00 00 00 00 64 22 08 
3 1 44 15 02 16 02 03 05 00 00 00 00 00 00 00 00 57 58 
3 2 85 32 83 09 00 00 21 00 00 00 00 00 00 00 55 75 82 
3 3 00 00 00 00 00 00 00 00 00 00 00 00 00 00 79 00 00 
4 1 38 24 08 15 00 12 10 00 00 00 00 00 00 00 00 37 13 
4 2 48 27 12 27 00 15 14 00 00 00 00 00 00 00 00 70 50 
4 3 02 00 00 00 00 00 00 00 00 00 00 00 00 00 00 04 00 
111 1 1 18 02 01 02 02 15 16 24 13 08 08 03 03 59 11 41 67 
1 2  67 04 03 05 07 06 11 21 16 03 04 03 03 48 21 60 72 
1 3 17 03 03 02 04 03 04 11 06 09 10 09 09 60 28 17 54 
2 1 17 05 04 04 06 11 13 18 09 09 10 03 03 36 48 70 78 
2 2 49 09 04 03 05 12 11 17 09 08 08 02 01 33 36 67 83 
2 3 15 03 02 02 03 03 03 04 03 04 04 04 03 54 22 12 17 
3 1 29 03 05 05 08 07 06 07 08 04 10 02 01 47 46 26 50 
3 2 45 13 02 02 04 05 22 23 14 12 04 03 04 36 27 36 60 
3 3 13 04 02 04 06 05 05 16 03 08 09 02 03 49 47 14 39 
4 1 66 07 03 02 04 03 14 52 31 07 08 09 10 56 20 42 71 
4 2 25 05 05 05 07 06 06 17 15 05 04 04 04 42 44 50 73 
4 3 05 05 05 05 05 06 06 14 03 03 06 04 05 59 31 12 17 
112 1 1 42 06 06 04 00 14 51 00 51 15 05 00 00 22 06 46 73 
1 2  51 03 07 00 00 06 33 54 58 19 32 09 03 33 29 55 79 
1 3  00 00 00 00 00 00 00 10 02 15 18 00 00 74 11 07 02 
96 
ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
112 2 1 68 05 12 00 00 05 16 31 30 38 50 00 08 22 69 78 88 
2 2 77 42 09 00 00 04 22 29 21 42 50 00 06 30 79 91 87 
2 3 10 04 00 00 00 03 00 00 03 30 34 00 03 78 19 46 24 
3 1 22 03 27 33 04 42 52 52 52 25 41 02 11 24 42 53 72 
3 2 56 06 30 12 21 07 26 44 48 27 26 03 06 24 57 72 71 
3 3 16 01 01 01 10 01 01 15 03 17 17 01 07 21 71 06 05 
4 1 71 25 20 04 03 12 42 41 41 03 03 00 34 21 80 75 83 
4 2 66 47 46 00 00 28 40 44 45 03 07 00 06 12 86 83 87 
4 3 09 00 00 00 00 05 00 03 05 00 03 00 03 43 52 05 02 
113 1 1 19 00 00 00 00 00 00 00 02 00 00 00 00 60 00 39 51 
1 2  32 00 00 00 00 00 00 04 00 00 00 02 00 49 00 40 52 
1 3  15 00 00 00 00 00 00 00 00 00 00 00 00 65 01 10 14 
2 1 23 00 00 00 00 00 00 00 00 00 00 00 00 60 00 59 63 
2 2 55 00 00 00 00 00 00 00 00 00 05 00 00 47 00 67 69 
2 3 00 00 00 00 00 00 00 00 00 00 00 00 00 62 00 15 09 
3 1 00 00 00 00 00 00 00 00 00 00 00 00 00 63 06 10 10 
3 2 04 01 00 00 00 00 00 00 00 00 00 00 00 41 00 05 12 
3 3 00 00 00 00 00 00 00 00 00 00 00 00 00 65 00 04 02 
4 1 12 01 01 01 00 00 01 00 00 00 00 00 00 59 01 60 66 
4 2 28 01 01 01 00 00 00 00 01 00 00 00 00 64 00 62 62 
4 3 04 00 00 00 00 00 00 01 01 00 00 00 00 69 00 03 05 
Variables Doses T imes 
01 Emptiness 1 5 .  .04 g ALA 1 11 :00 am 
02 Rumbling 2 0.84 g PHE 2 11:45 am 
03 Stomach Ache 3 2.  ,52 g PHE 3 i 12:30 pm 
04 Nausea 4 5.  .04 g PHE 
05 Headache 
06 Dizziness 
07 Faintness 
08 Drowsy 
09 Weak 
10 Nervous 
11 Tense 
12 Drugged 
13 Depressed 
14 Alert  
15 Mentally s low 
16 Hunger 
17 Urge to eat 
ID 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
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Energy Intakes (kcal)  
Experiment 2 
Placebo 
10.08 g ALA 5.04 g AIM 10.08 g APM 10.08 g PHE 
644.0 -598.7 628.7 623.9 
1215.9 1021.9 1019.4 997.4 
1539.1 1379.6 1601.4 1345.3 
1026.3 971.9 849.1 988.9 
1386.9 1297.3 1905.0 1573.9 
832.4 798.6 1086.3 764.2 
1350.9 1678.3 1532.4 947.7 
1002.1 1223.0 858.5 566.4 
1498.5 1029.6 785.7 1155.5 
1839.9 1424.9 1404.3 1643.1 
729.4 499.9 542.5 433.5 
1720.3 941.5 1199.8 1520.5 
1202.0 1468.3 1192.9 1349.3 
Protein Intakes { % )  
Experiment 2 
14.2 13.2 15.1 12.5 
18.2 16.9 17.1 17.6 
15.0 21.3 • 14.9 12.3 
15.4 14.3 12.4 12.1 
16.7 15.2 15.0 17.3 
9.6 9.8 8.9 9.6 
15.5 16.8 16.8 18.1 
20.5 18.6 17.1 23.2 
18.8 15.4 16.5 18.3 
22.5 22.4 22.1 20.7 
20.5 21.1 19.8 15.9 
15.3 17.4 15.2 20.3 
15.0 11.6 11.8 11.6 
Carbohydrate Intakes (%) 
Experiment 2 
42.5 44.6 51.0 43.5 
40.0 49.4 42.0 41.2 
29.7 30.3 31.8 39.8 
34.8 35.4 40.4 38.8 
34.1 33.7 33.1 32.1 
46.6 48.5 49.4 43.8 
37.4 32.0 30.7 29.2 
37.1 30.6 29.0 30.6 
31.0 35.0 36.5 31.0 
25.2 25.0 28.1 31.1 
34.0 39.6 40.9 42.9 
39.8 43.2 42.1 31.8 
33.3 39.7 39.8 41.6 
ID 
201" 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
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Fat Intake (%) 
Experiment 2 
Placebo 
.08 g ALA 5.04 g APM 10 .08 g APM 10.08 g PHE 
43.0 41.8 33.8 43.9 
41.7 33.4 40.9 41.1 
55.7 48.5 53.8 48.3 
50.2 50.8 47.8 49.5 
49.6 51.8 52.9 50.9 
44.0 42.3 42.4 47.0 
47.8 51.8 52.9 53.0 
42.7 51 .4  54.5 46.1 
50.0 49.8 46.7 50.5 
52.5 52.9 49.8 48.5 
45.3 38.3 39.0 40.7 
45.1 39.3 42.8 48.5 
52.1 47.8 
Carbohydrate/Protei  n 
Experiment 2 
49.0 47.4 
3.0 3.4 3.4 3.5 
2.2 2.9 2.5 2.3 
2.0 1.4 2.1 3.2 
2.3 2.5 3.3 3.2 
2.0 2.2 2.2 1.9 
4.8 5.0 5.5 4.6 
2.4 1.9 1.8 1.6 
1.8 1.6 1.7 1.3 
1.6 2.3 2.2 1.7 
1.1 1.1 1.3 1.5 
1.7 1.9 2.0 2.7 
2.6 2.5 2.8 1.6 
2.2 3.4 3.5 3.6 
Total  Food Consumed (dry wt. ,  g)  
Experiment 2 
122.0 114.2 127.6 147.7 
233.3 207.1 197.1 192.1 
267.3 252.2 282.5 247.6 
185.9 175.5 157.3 180.3 
252.7 233.5 340.8 283.3 
157.6 153.8 209.7 141.9 
250.3 301.2 272.2 167.9 
191.8 220.1 150.9 105.2 
270.0 186.8 144.9 207.2 
326.6 252.8 254.1 301.3 
136.0 97.2 105.8 83.3 
322.9 183.6 228.9 279.8 
214.7 266.3 219.0 250.3 
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Plasma Amino Acid Levels  (umoles/dl)  
Experiment 2 
ID ALA TYR VAL ILE TRP LEU PHE 
Placebo (10.08 q ALA) 
Baseline 
202 41.7 7.9 25.9 8.7 7.7 16.4 6.4 
203 49.0 7.4 5.2 5.7 9.0 13.1 6.2 
204 63.7 8.9 26.1 9.8 6.3 17.0 6.5 
205 25.5 3.2 13.8 5.0 5.2 10.4 4.1 
207 129.7 8.7 25.3 7.7 8.3 16.3 6.3 
209 57.7 9.6 25.9 10.0 9.0 20.0 6.7 
210 54.0 9.4 8.7 9.0 7.6 18.8 8.1 
Experimental  
202 69.5 10.5 26.0 7.3 6.7 15.8 5.2 
203 120.0 8.7 21.1 4.6 7.9 9.3 4.4 
204 88.9 3.7 19.8 6.0 4.1 14.0 4.6 
205 82.7 6.1 22.1 6.3 5.9 16.6 5.6 
207 47.7 7.0 18.8 7.2 , 6 .9 14.4 6.0 
209 129.4 11.1 25.9 6.8 7.2 14.6 5.4 
210 85.4 9.4 11.0 6.9 5.2 16.4 5.9 
5.04 q APM 
Baseline 
202 74.3 6.5 28.4 7.4 8.2 17.3 10.9 
203 61.6 10.6 29.8 9.1 10.9 19.2 9.1 
204 50.6 7.6 24.0 8.9 5.3 15.1 5.5 
205 57.5 4.4 15.3 10.0 6.6 11.1 8.5 
207 48.0 5.9 26.5 9.0 9.8 19.1 6.8 
209 41.9 13.1 25.4 9.3 8.8 18.2 6.4 
210 42.2 5.2 4.7 6.6 5.0 13.2 5.8 
Experimental  
202 55.9 10.9 28.0 9.4 9.3 18.2 7.1 
203 94.1 8.3 27.3 7.6 9.4 16.0 20.8 
204 109.1 12.3 24.2 10.0 5.7 19.9 11.7 
205 63.7 8.8 15.1 7.4 5.0 9.6 11.4 
207 71.4 11.1 18.6 5.4 6.1 12.4 14.7 
209 62.7 8.3 26.5 6.6 7.2 14.9 11.5 
210 82.7 11 .2  25.2 7.8 5.2 15.7 14.3 
100 
ID ALA TYR VAL ILE TRP LEU PHE 
10.08 q APM 
Baseline 
202 31.3 4.4 22.0 6.6 7.1 12.3 5.5 
203 54.1 8.4 20.8 6.6 10.6 12.9 6.3 
204 72.8 3.2 24.5 10.2 5.0 19.2 6.6 
205 47.3 9.8 25.3 8.8 10.4 15.9 6.8 
207 65.5 8.9 31.1 11 .6  9.8 20.1 7.0 
209 48.6 7.2 33.1 12.5 ' 10.3 22.2 9.5 
210 45.5 6.9 29.1 8.4 7.2 19.3 7.0 
Experimental  
202 79.9 13.0 28.7 7.1 7.8 15.2 12.2 
203 39.8 10.4 14.0 3.4 5.7 7.5 36.6 
204 89.3 16.5 25.2 9.1 4.9 17.8 31.7 
205 30.4 10.1 13.2 4.8 5.9 9.2 17.8 
207 58.9 6.3 20.7 7.8 6.5 15.5 28.8 
209 62.8 12.9 22.0 6.3 6.5 14.4 28.6 
210 48.8 12.4 5.2 6.7 6.2 15.1 28.1 
10.08 q PHE 
Baseline 
202 49.2 8.7 29.8 9.5 10.7 18.8 12.2 
203 61.7 7.9 25.2 7.9 10.8 16.3 6.7 
204 94.2 12.1 32.2 10.2 6.8 20.7 6.6 
205 48.3 9.0 24.9 8.8 9.0 17.4 9.1 
207 35.0 3.8 2.9 5.8 6.6 12.7 5.7 
209 56.9 9.5 7.8 10.1 9.1 18.0 6.7 
210 55.9 8.7 28.8 9.3 9.4 18.5 7.1 
Experimental  
202 39.9 14.8 24.1 6.5 7.0 15.0 24.1 
203 45.9 22.1 22.2 7.0 8.1 14.7 59.2 
204 51.9 13.7 31.4 10.1 7.0 12.1 80.5 
205 56.7 26.9 21.1 10.1 7.5 23.0 97.1 
207 43.3 9.8 5.2 6.9 6.9 15.6 139.8 
209 50.3 15.3 17.9 5.2 4.9 10.2 92.7 
210 42.7 14.4 24.2 6.1 5.3 13.8 92.9 
s 
T 
l 
i 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
1 
1 
1 
2 
2 
3 
3 
4 
4 
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Visual Analog Scale Scores 
Experiment 2 
Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
1 00 00 00 00 03 04 00 00 00 00 00 00 00 97 00 00 26 
2 30 00 00 00 00 00 00 00 00 00 00 00 00 99 00 49 67 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
1 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
2 26 00 00 00 00 00 00 00 00 00 00 00 00 99 00 04 19 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
1 03 00 00 00 00 00 00 00 00 00 00 00 00 83 00 00 10 
2 43 00 00 00 00 00 00 00 00 00 00 00 00 76 00 52 45 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 •00 00 
1 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 12 
2 34 00 00 00 00 00 00 00 00 00 00 00 00 99 00 28 50 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
1 00 00 00 00 00 00 00 08 00 00 00 00 00 50 00 00 00 
2 02 00 00 00 00 00 00 00 00 00 00 00 00 51 00 08 09 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 49 00 00 00 
1 09 00 00 00 00 00 00 00 00 00 00 00 00 45 00 06 05 
2 22 00 00 00 00 00 00 00 00 00 00 00 00 58 00 24 20 
3 00 00 00 00 00 00 00 02 00 00 00 00 00 56 00 00 00 
1 00 00 00 00 00 00 00 02 00 00 00 00 00 49 48 02 02 
2 01 00 00 00 00 00 00 00 00 00 00 00 00 50 51 04 04 
3 00 00 00 00 00 00 00 14 00 00 00 00 00 49 48 00 00 
1 05 00 00 02 00 00 00 02 00 00 00 00 00 47 00 06 08 
2 02 00 00 00 00 00 00 00 00 00 00 00 00 51 00 17 27 
3 00 00 00 00 00 00 00 00 00 00 00 00 00 46 00 00 00 
1 03 00 00 00 .00 00 00 00 03 04 00 00 00 68 06 03 00 
2 42 00 00 00 00 00 00 15 02 00 00 00 00 72 04 41 27 
3 00 00 00 00 00 00 00 04 00 00 00 00 00 90 08 00 04 
1 33 00 08 00 00 00 04 05 36 00 00 00 14 33 33 21 47 
2 28 00 00 00 00 00 00 05 11 00 00 00 00 59 07 24 35 
3 00 00 00 00 00 00 00 08 08 00 00 00 00 60 01 00 05 
1 00 00 00 00 00 00 00 02 01 00 00 00 00 75 05 03 00 
2 22 00 00 00 00 00 00 00 04 00 00 00 00 92 06 35 17 
3 00 00 00 00 00 00 00 00 01 00 00 03 00 94 00 00 00 
1 00 00 00 00 00 00 00 04 00 00 00 00 00 87 00 00 03 
2 10 00 00 00 50 00 00 12 00 00 00 00 00 81 08 34 31 
3 00 00 00 00 04 00 00 31 00 00 00 00 00 92 05 00 00 
1 20 06 18 05 48 20 17 47 46 26 17 18 08 90 12 11 04 
2 12 08 07 10 41 43 58 61 18 15 14 65 12 53 13 52 60 
3 14 11 12 02 05 05 06 09 09 09 03 52 09 73 79 15 25 
1 12 02 03 05 03 04 06 12 14 06 10 11 11 85 16 22 82 
2 11 11 75 55 50 59 64 57 61 45 42 72 65 85 55 27 85 
2 20 06 03 03 21 29 07 23 10 10 11 28 08 50 51 47 32 
3 11 04 03 03 40 45 44 15 14 13 11 09 09 72 54 22 20 
1 54 05 04 04 04 04 03 02 04 04 02 03 04 86 04 34 60 
2 21 01 02 02 17 22 07 22 15 01 00 69 03 77 01 45 39 
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ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
204 4 3 12 01 01 02 19 29 06 04 04 02 02 53 02 75 61 14 13 
205 1 1 25 00 00 06 14 14 00 74 27 00 11 43 14 13 23 39 42 
1 2 32 19 06 06 06 00 06 24 07 00 14 16 12 37 30 55 33 
1 3 00 00 06 07 14 00 00 19 12 00 22 14 00 39 27 00 00 
2 1 56 15 00 20 57 46 22 50 28 15 19 39 16 32 32 52 32 
2 2 32 11 00 00 36 17 00 57 41 00 00 00 00 53 49 55 24 
2 3 14 00 00 00 23 00 00 27 17 00 00 00 00 58 17 18 04 
3 1 25 00 00 00 15 15 00 54 16 00 00 16 00 36 33 39 52 
3 2 45 11 00 00 14 14 00 48 17 00 00 14 13 28 28 58 57 
3 3 84 00 14 00 23 00 00 33 04 00 00 00 00 60 15 00 00 
4 1 26 04 31 00 00 00 00 26 08 00 09 00 15 41 12 28 26 
4 2 57 19 06 05 41 25 00 25 05 00 09 20 04 56 13 63 69 
4 3 00 00 00 12 16 06 00 28 00 00 00 23 00 46 18 00 00 
206 1 1 23 03 05 05 05 07 08 35 03 04 06 06 07 72 05 16 22 
1 2  43 03 04 04 03 03 02 12 02 02 04 04 04 69 16 56 46 
1 3  07 01 02 02 03 03 03 15 02 03 03 04 05 64 16 11 05 
2 1 32 05 16 03 03 03 03 02 03 03 03 03 04 62 18 29 50 
2 2 65 02 03 03 03 03 03 20 03 04 04 04 05 70 22 57 59 
2 3 07 02 03 03 11 02 03 03 03 03 04 03 04 55 04 12 15 
3 1 15 02 03 04 03 04 03 02 02 02 02 03 03 80 07 26 57 
3 2 49 04 05 06 06 06 05 03 03 03 03 04 05 67 04 46 48 
3 3 03 03 12 11 07 08 09 19 06 06 07 09 09 71 06 04 03 
4 1 28 03 03 03 03 03 03 47 07 01 01 01 02 50 19 14 44 
4 2 26 02 02 02 18 03 03 16 02 02 02 03 03 42 21 45 46 
4 3 03 04 04 04 21 03 04 12 04 04 04 05 05 45 24 03 04 
207 1 1 00 00 00 00 00 10 00 00 00 00 00 00 00 99 00 00 00 
1 2 13 00 00 00 00 07 00 00 00 00 00 00 00 99 00 12 18 
1 3  00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
2 1 00 00 00 00 00 00 00 06 00 00 06 00 00 87 00 00 00 
2 2 08 00 10 00 00 00 00 22 00 00 04 00 00 53 23 11 07 
2 3 00 00 00 00 00 00 00 00 00 00 00 00 00 82 00 00 00 
3 1 00 00 00 00 00 05 00 22 17 00 00 00 00 66 27 00 00 
3 2 12 11 00 00 00 00 00 00 00 00 00 00 00 99 00 40 55 
3 3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
4 1 00 00 00 00 00 00 00 11 00 00 00 00 00 72 03 00 00 
4 2 00 00 04 00 00 00 00 36 00 00 00 00 00 63 22 00 00 
4 3 00 00 00 00 00 00 00 05 00 00 00 00 00 90 07 00 00 
208 1 1 14 03 03 02 02 01 00 02 02 02 02 00 01 55 05 11 04 
1 2  40 05 03 02 00 00 00 40 00 00 16 00 00 69 05 44 35 
1 3  00 00 00 00 00 00 00 00 00 00 00 00 00 56 10 00 05 
2 1 03 04 01 02 03 02 03 52 35 34 05 02 02 22 36 00 03 
2 2 29 01 01 02 02 01 02 56 33 36 00 02 02 27 45 00 37 
2 3 00 00 00 00 00 00 00 33 22 00 00 00 00 39 29 00 07 
3 1 33 11 00 02 22 01 02 02 02 00 00 00 00 52 16 20 14 
3 2 25 04 01 16 00 00 00 38 00 00 00 00 00 32 00 22 18 
3 3 03 03 03 08 03 03 02 19 05 38 03 04 04 55 08 04 00 
4 1 04 05 03 17 56 22 02 40 39 02 02 02 03 43 05 03 00 
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ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
208 4 2 02 00 00 00 00 00 00 76 00 02 00 00 00 30 07 00 02 
4 3 06 -03 02 00 03 03 02 17 02 02 02 02 03 75 08 02 01 
209 1 1 20 00 00 00 00 00 00 00 00 00 00 00 00 99 00 27 00 
1 2  51 00 00 00 00 00 00 00 00 00 00 00 00 99 00 48 29 
1 3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
2 1 28 00 00 00 00 00 00 25 25 00 00 00 00 77 00 00 00 
2 2 39 00 00 00 00 00 00 00 00 00 00 00 00 94 00 49 35 
2 3 00 00 00 00 00 00 00 00 00 00 00 00 00 92 00 00 00 
3 1 18 00 00 00 00 00 00 24 23 00 00 00 00 73 18 00 00 
3 2 17 00 00 00 00 00 00 00 00 00 00 00 00 89 04 22 05 
3 3 00 00 00 00 00 00 00 00 00 00 00 00 00 89 07 00 00 
4 1 45 00 00 00 00 00 00 24 23 00 00 00 00 81 13 00 00 
4 2 68 00 00 00 00 00 00 00 00 00 00 00 00 86 06 50 46 
4 3 00 00 00 00 00 00 00 00 00 00 00 00 00 99 00 00 00 
210 1 1 26 22 04 04 05 04 04 07 07 06 06 04 04 77 06 22 21 
1 2  48 29 06 04 05 04 04 07 06 06 05 05 05 83 03 46 43 
2 1 05 10 03 03 06 04 04 07 06 06 06 05 05 93 05 32 37 
2 2 42 26 05 05 05 07 06 08 07 07 06 05 06 76 04 63 66 
2 3 03 03 03 04 04 03 02 03 03 02 03 03 02 77 03 13 04 
3 1 18 18 04 03 06 05 03 05 03 03 03 03 04 73 01 02 17 
3 2 53 27 03 04 05 05 05 04 05 05 05 05 05 88 03 51 35 
3 3 03 03 03 03 04 06 04 03 03 03 05 05 08 83 04 05 04 
4 1 30 24 08 22 08 08 06 07 06 07 07 05 06 79 08 21 21 
4 2 45 26 09 11 09 07 07 11 08 07 07 09 08 79 06 46 52 
4 3 05 05 04 05 06 08 08 08 07 07 05 04 04 85 03 04 04 
211 1 1 03 00 00 00 08 00 00 20 07 03 18 00 03 55 03 00 00 
1 2  53 00 00 00 02 00 00 12 03 00 04 00 00 78 03 99 53 
1 3  03 00 00 00 03 00 00 31 02 00 02 00 02 85 05 00 00 
2 1 05 00 00 00 00 00 00 07 00 00 05 00 00 88 00 51 18 
2 2 71 00 00 00 00 00 00 18 00 00 08 00 00 84 00 56 55 
2 3 07 00 00 00 04 00 00 25 00 00 00 00 00 81 00 00 00 
3 1 00 00 00 00 04 00 00 05 03 00 00 00 04 59 05 00 00 
3 2 04 00 00 00 04 00 00 00 00 00 00 00 00 87 00 00 00 
3 3 00 00 00 00 00 00 00 08 00 00 00 00 04 68 00 00 00 
4 1 04 00 00 00 00 00 00 03 00 00 21 00 00 50 00 48 49 
4 2 56 00 00 00 00 00 00 00 00 00 00 00 00 53 00 68 49 
4 3 00 00 00 00 00 00 00 20 00 00 00 00 00 35 03 00 00 
212 1 1 07 05 05 05 01 01 01 12 02 02 01 02 03 65 07 13 13 
1 2  29 17 03 02 02 02 02 27 04 02 02 03 03 66 18 43 44 
1 3  01 01 01 01 01 01 01 17 02 02 02 02 02 68 22 08 07 
2 1 04 02 03 03 04 04 04 15 06 06 05 05 06 55 15 11 07 
2 2 05 04 04 05 05 05 05 20 05 06 06 06 06 56 19 22 28 
2 3 03 05 05 08 05 07 08 07 08 08 08 08 08 55 24 04 06 
3 1 13 04 06 04 02 04 04 20 04 05 05 07 07 62 26 10 10 
3 2 05 07 06 06 04 05 04 15 05 02 03 03 03 65 14 44 46 
3 3 01 03 04 03 03 03 02 06 02 04 04 05 04 65 18 01 03 
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Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
4 1 00 00 00 00 00 00 00 25 00 10 00 00 00 70 43 17 17 
4 2 29 00 00 14 00 00 00 25 00 09 09 00 00 53 49 48 47 
4 3 60 00 00 01 00 00 00 22 01 01 01 01 01 63 26 12 10 
1 1 46 14 06 07 01 04 04 28 14 03 01 00 02 43 38 39 54 
1 2  72 34 17 02 00 00 01 02 03 01 00 02 02 83 03 71 78 
1 3  00 00 00 00 00 00 00 07 00 00 00 00 00 88 00 01 04 
2 1 68 58 34 31 62 60 75 85 38 02 00 02 03 22 85 78 81 
2 2 47 47 40 16 35 13 16 20 10 02 02 02 04 68 27 78 85 
2 3 00 00 00 00 00 00 00 09 00 00 00 00 00 87 00 04 12 
3 1 35 02 02 04 18 02 02 35 04 00 00 00 00 43 42 44 47 
3 2 74 70 64 49 42 58 54 66 60 00 02 04 03 31 31 77 82 
3 3 00 00 00 00 00 00 00 19 00 00 00 00 00 77 04 00 08 
4 1 70 49 09 00 00 02 09 94 26 03 07 00 00 35 57 45 45 
4 2 43 28 02 00 02 02 00 00 00 00 00 00 00 53 06 88 64 
4 3 00 00 00 00 00 00 00 07 00 00 00 00 00 82 00 00 02 
Variables Doses Times 
01 Emptiness 1 10.08 g ALA 1 10:00 am 
02 Rumbling 2 5.04 g APM 2 11:30 am 
03 Stomach Ache 3 10.08 g APM 3 12:45 pm 
04 Nausea 4 10.08 g PHE 
05 Headache 
06 Dizziness 
07 Faintness 
08 Drowsy 
09 Weak 
10 Nervous 
11 Tense 
12 Drugged 
13 Depressed 
14 Alert  
15 Mentally s low 
16 Hunger 
17 Urge to eat 
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Plasma Amino Acid Levels  (jumoles/dl)  
Experiment 3 
ID ALA TYR VAL ILE TRP LEU PHE 
Carbohydrate + 10.08 g ALA 
Baseline 
301 
302 
304 
305 
306 
307 
Experimental  
301 64.1 6.4 2.4 4.4 4.5 8.2 5.0 
302 101.3 5.1 18.4 6.7 6.8 13.4 5.6 
304 84.1 6.5 13.9 4.6 5.4 9.4 5.3 
305 126.5 4.7 24.1 6.9 9.2 . 13.7 6.7 
306 108.3 8.7 22.8 5.4 6.1 12.0 5.0 
307 '  69.3 7.3 22.2 5.6 • 6 .0 11.3 7.5 
Carbohydrate + 10.08 g APM 
Baseline 
301 
302 
304 
305 
306 
307 
Experimental  
301 36.4 7.3 3.1 5.4 5.5 10.1 10.6 
302 55.5 15.4 23.3 6.2 8.1 13.5 21.4 
304 54.9 8.0 16.1 5.8 6.7 11.2 9.1 
305 32.9 11.8 24.0 7.2 8.0 13.1 13.4 
306 63.3 13.8 14.0 5.6 5.6 9.9 23.4 
307 46.6 7.8 19.4 5.1 6.3 10.7 13.9 
21.4 7.3 3.2 6.5 6.2 12.0 5.9 
37.6 10.6 25.6 8.2 8.5 16.1 6.7 
39.1 7.7 21.2 8.5 7.4 15.4 7.1 
26.8 6.8 25.4 8.6 9.8 17.0 6.6 
42.6 10.9 25.4 7.2 9.6 18.9 6.7 
29.3 8.0 24.5 7.3 6.8 15.1 8.0 
32.3 9.3 3.5 6.4 6.2 12.8 5.4 
35.6 9.2 19.3 6.8 8.3 15.0 6.3 
32.2 8.2 18.4 8.6 6.7 16.5 6.5 
27.1 10.0 28.0 9.0 8.5 18.0 7.0 
30.8 8.2 17.3 6.4 6.5 11.4 4.8 
29.4 7.2 26.2 7.4 7.1 13.9 8.2 
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Visual Analog Scale Scores 
Experiment 3 
ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
W\ 1 T 13 64 49 06 01 13 14 11 01 01 00 00 01 27 64 05 00 
1 2  36 07 07 01 01 13 23 39 27 06 04 00 01 33 38 29 01 
1 3  08 43 47 52 57 58 62 53 36 02 02 00 01 21 74 15 06 
1 4 01 48 49 49 48 20 13 27 27 02 02 01 01 32 54 09 02 
2 .1 * 01 01 01 01 01 32 16 58 32 00 00 01 00 55 44 01 02 
2 2 40 20 17 25 01 28 14 27 01 00 01 01 00 59 25 53 45 
2 3 17 02 01 02 03 02 02 49.31 01 01 01 00 62 13 35 36 
2 4 00 00 00 00 00 00 00 00 00 00 00 00 04 32 41 09 10 .  
302 1 1 04 00 00 00 04 00 00 05 00 00 00 00 00 73 00 07 05 ' 
1 2  41 00 05 00 00 00 00 06 00 00 00 00 00 79 00 64 63 
1 3  34 00 06 00 04 00 00 04 00 00 00 00 00 60 00 47 48 
1 4  06 00 00 00 17 00 00 07 00 00 00 00 00 75 00 14 10 
2 1 18 00 00 00 00 00 00 08 00 00 00 00 00 70 00 15 24 
2 2 80 14 20 00 18 00 00 06 00 00 00 00 00 72 00 72 68 
2 3 48 07 25 00 30 06 00 32 08 00 00 00 00 65 07 62 64 
2 4 38 00 00 00 48 15 00 15 00 00 00 00 00 56 07 29 18 
304 1 1 13 05 05 01 02 02 02 12 10 02 01 00 04 79 18 35 34 
1 2 .  35 09 06 00 00 02 02 13 13 03 01 05 05 62 34 42 40 
1 3  54 22 05 02 18 07 07 05 06 03 02 00 00 83 14 62 63 
1 4  01 00 31 32 25 21 31 37 30 15 11 07 04 56 36 05 01 
2  1 13 01 04 03 05 06 07 11 00 04 04 00 00 70 21 21 22 
2  2 24 10 09 02 02 04 03 06 03 06 07 00 00 73 19 36 34 
2 3 35 34 02 02 02 00 00 04 01 03 03 00 00 81 20 40 48 
2 4 28 12 01 00 03 00 02 03 00 07 05 00 04 84 09 30 32 
305 1 1 11 00 00 00 21 03 00 47 20 02 02 00 00 43 44 07 08 
1 2  65 14 12 00 17 07 01 50 22 02 17 01 00 50 11 27 34 
1 3 38 10 01 01 26 05 02 65 19 02 02 02 01 63 23 47 45 
1 4  07 02 01 01 30 02 02 29 07 02 01 01 01 70 20 01 02 
2 1 15 01 13 03 06 02 02 25 19 05 02 01 02 52 46 10 08 
2 2 27 02 02 01 18 02 02 22 17 02 02 01 01 68 26 25 24 
2 4 14 02 02 10 10 02 02 08 02 02 02 02 01 74 13 05 02 
306 1 1 03 03 03 03 03 03 04 91 04 04 04 04 04 44 44 07 08 
1 2  06 06 05 23 08 07 08 41 10 10 08 07 07 48 24 06 05 
1 3 22 04 04 05 03 04 50 05 06 06 04 05 05 68 19 23 22 
1 4  05 05 05 05 04 05 06 07 07 06 07 07 07 70 16 05 05 
2 1 00 00 00 00 00 00 00 24 00 00 00 00 00 28 27 00 00 
2 2 03 00 00 00 00 00 00 14 00 00 00 00 00 43 04 07 08 
2 3 20 00 00 00 00 00 00 03 00 00 00 00 00 77 02 35 34 
2 4 00 00 00 00 00 00 00 01 00 00 00 00 00 99 02 10 09 
107 
ID Dose Time 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 
307 1 1 03 01 ol 01 01 01 Ol 11 01 01 01 01 01 62 02 04 03 
1 2  02 01 01 00 01 01 01 04 04 01 01 01 02 73 01 01 01 
1 3  02 02 01 02 02 01 01 03 03 01 01 01 01 89 02 03 04 
1 4  04 03 01 03 02 02 02 02 02 03 02 02 03 82 04 03 03 
2 1 00 00 00 00 00 05 00 05 00 00 00 00 00 80 00 00 00 
2 2 00 00 00 00 00 00 00 00 00 00 00 00 00 76 00 00 00 
2 3 08 00 00 00 00 00 00 02 00 00 00 00 00 84 00 10 10 
2 4 00 00 00 00 00 00 00 31 00 00 00 00 00 80 00 00 00 
Variables Doses Times 
01 Emptiness 1 10.08 g APM 1 8:00 am 
02 Rumbling 2 10.08 g ALA 2 10:00 am 
03 Stomach Ache 3 12:00 noon 
04 Nausea 4 2:00 pm 
05 Headache 
06 Dizziness 
07 Faintness 
08 Drowsy 
09 Weak 
10 Nervous 
11 Tense 
12 Drugged 
13 Depressed 
14 Alert  
15 Mentally s low 
16 Hunger 
17 Urge to eat 
